CYP2C9 Human (-)-anisomycin multiple interactions ISO Cyp2c65 (Mus musculus) 6480464 [Anisomycin co-treated with 1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with NR1I3 protein] results in increased expression of CYP2C9 mRNA CTD PMID:23539296 CYP2C9 Human (1->4)-beta-D-glucan multiple interactions ISO Cyp2c65 (Mus musculus) 6480464 [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of CYP2C65 mRNA CTD PMID:36331819 CYP2C9 Human (E,E)-germacrone decreases activity EXP 6480464 germacrone results in decreased activity of CYP2C9 protein CTD PMID:23850985 CYP2C9 Human (R)-lipoic acid multiple interactions EXP 6480464 Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated more ... CTD PMID:24120545 CYP2C9 Human (S)-naringenin multiple interactions EXP 6480464 naringenin inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] CTD PMID:21053930 CYP2C9 Human (S)-naringenin decreases activity EXP 6480464 naringenin results in decreased activity of CYP2C9 protein CTD PMID:29753067 CYP2C9 Human 1,1,1-Trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane increases chemical synthesis EXP 6480464 CYP2C9 protein results in increased chemical synthesis of 1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane CTD PMID:9733665 CYP2C9 Human 1,2-dichloroethane increases expression ISO Cyp2c65 (Mus musculus) 6480464 ethylene dichloride results in increased expression of CYP2C65 mRNA CTD PMID:28960355 CYP2C9 Human 1,2-dimethylhydrazine decreases expression ISO Cyp2c65 (Mus musculus) 6480464 1,2-Dimethylhydrazine results in decreased expression of CYP2C65 mRNA CTD PMID:22206623 CYP2C9 Human 1,2-dimethylhydrazine multiple interactions ISO Cyp2c65 (Mus musculus) 6480464 [1,2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of CYP2C65 mRNA CTD PMID:22206623 CYP2C9 Human 1,4-naphthoquinone increases abundance EXP 6480464 CYP2C9 protein results in increased abundance of 1,4-naphthoquinone CTD PMID:16243959 CYP2C9 Human 1-aminobenzotriazole multiple interactions EXP 6480464 1-aminobenzotriazole inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Diclofenac] CTD PMID:15618748 CYP2C9 Human 1-aminobenzotriazole decreases activity EXP 6480464 1-aminobenzotriazole results in decreased activity of CYP2C9 protein CTD PMID:11375247 CYP2C9 Human 1-naphthol increases abundance EXP 6480464 CYP2C9 protein results in increased abundance of 1-naphthol CTD PMID:16243959 CYP2C9 Human 1-naphthyl isothiocyanate multiple interactions EXP 6480464 [1-Naphthylisothiocyanate co-treated with Cholic Acids] affects the expression of CYP2C9 mRNA CTD PMID:27344345 CYP2C9 Human 14,15-EET multiple interactions EXP 6480464 Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid] CTD PMID:12675279 CYP2C9 Human 14,15-EET increases chemical synthesis EXP 6480464 CYP2C9 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid CTD PMID:12675279 CYP2C9 Human 17alpha-ethynylestradiol increases hydroxylation EXP 6480464 CYP2C9 protein results in increased hydroxylation of Ethinyl Estradiol CTD PMID:15304426 CYP2C9 Human 17beta-estradiol multiple interactions EXP 6480464 [ESR1 protein co-treated with MED25 protein co-treated with Estradiol] results in increased activity of CYP2C9 more ... CTD PMID:21768169|PMID:27273787 CYP2C9 Human 17beta-estradiol increases activity EXP 6480464 Estradiol results in increased activity of CYP2C9 protein CTD PMID:22837389 CYP2C9 Human 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of CYP2C9 mRNA CTD PMID:16985168 CYP2C9 Human 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO Cyp2c65 (Mus musculus) 6480464 Tetrachlorodibenzodioxin results in increased expression of CYP2C65 mRNA CTD PMID:28213091 CYP2C9 Human 2-(3,4-dimethoxyphenyl)-5-\{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino\}-2-(propan-2-yl)pentanenitrile decreases activity ISO Cyp2c65 (Mus musculus) 6480464 Verapamil results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human 2-n-Propyl-4-pentenoic acid increases chemical synthesis EXP 6480464 CYP2C9 protein results in increased chemical synthesis of 2-propyl-4-pentenoic acid CTD PMID:16945988 CYP2C9 Human 2-nitroanisole increases oxidation EXP 6480464 CYP2C9 protein results in increased oxidation of 2-nitroanisole CTD PMID:21218109 CYP2C9 Human 2-tert-butylhydroquinone increases expression EXP 6480464 2-tert-butylhydroquinone results in increased expression of CYP2C9 mRNA; 2-tert-butylhydroquinone results in increased expression of CYP2C9 more ... CTD PMID:24830941 CYP2C9 Human 2-tert-butylhydroquinone multiple interactions EXP 6480464 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [2-tert-butylhydroquinone results in increased expression of CYP2C9 mRNA]; 2-tert-butylhydroquinone promotes the more ... CTD PMID:24830941 CYP2C9 Human 3',4'-dimethoxyflavone multiple interactions EXP 6480464 3',4'-dimethoxyflavone inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] CTD PMID:21053930 CYP2C9 Human 3,3',5-triiodo-L-thyronine multiple interactions EXP 6480464 Triiodothyronine promotes the reaction [CYP2C9 protein results in increased metabolism of Coumarins] CTD PMID:14557374 CYP2C9 Human 4'-hydroxydiclofenac multiple interactions EXP 6480464 [[CYP2C9 protein co-treated with GSTP1 protein co-treated with Glutathione] results in increased hydroxylation of Diclofenac] more ... CTD PMID:24104198|PMID:24246759|PMID:25084468|PMID:29555536|PMID:31854189|PMID:35366062|PMID:35748891 CYP2C9 Human 4'-hydroxydiclofenac increases chemical synthesis EXP 6480464 CYP2C9 protein results in increased chemical synthesis of 4'-hydroxydiclofenac CTD PMID:12401345|PMID:15155557 CYP2C9 Human 4,4'-sulfonyldiphenol increases hydroxylation EXP 6480464 CYP2C9 protein results in increased hydroxylation of bisphenol S CTD PMID:27213244 CYP2C9 Human 4-[(1E)-1,2-diphenylbut-1-en-1-yl]phenol multiple interactions EXP 6480464 [CYP2C9 protein results in increased metabolism of 1-(4-hydroxyphenyl)-1,2-diphenyl-1-butene] which results in increased abundance of 1-(4-hydroxyphenyl)-1,2-diphenyl-1-butene more ... CTD PMID:29285606 CYP2C9 Human 4-[(1E)-1,2-diphenylbut-1-en-1-yl]phenol increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of 1-(4-hydroxyphenyl)-1,2-diphenyl-1-butene CTD PMID:29285606 CYP2C9 Human 4-[(1E)-1,2-diphenylbut-1-en-1-yl]phenol increases activity EXP 6480464 1-(4-hydroxyphenyl)-1,2-diphenyl-1-butene results in increased activity of CYP2C9 protein CTD PMID:29285606 CYP2C9 Human 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxybenzamide decreases activity EXP 6480464 Cisapride results in decreased activity of CYP2C9 protein CTD PMID:15306208 CYP2C9 Human 4-hydroxy-3-(2-hydroxy-3-oxo-1-phenylbutyl)-2H-chromen-2-one multiple interactions EXP 6480464 10-hydroxywarfarin binds to and results in decreased activity of CYP2C9 protein; 10-hydroxywarfarin inhibits the reaction more ... CTD PMID:20429590|PMID:20735727|PMID:27539372 CYP2C9 Human 4-hydroxy-3-[1-(4-hydroxyphenyl)-3-oxobutyl]-2H-chromen-2-one multiple interactions EXP 6480464 4'-hydroxywarfarin binds to and results in decreased activity of CYP2C9 protein; 4'-hydroxywarfarin inhibits the reaction more ... CTD PMID:20429590|PMID:20735727|PMID:27539372 CYP2C9 Human 4-Hydroxy-N-desmethyltamoxifen decreases activity EXP 6480464 4-hydroxy-N-desmethyltamoxifen results in decreased activity of CYP2C9 protein CTD PMID:29285606 CYP2C9 Human 4-hydroxycyclophosphamide increases chemical synthesis EXP 6480464 CYP2C9 protein results in increased chemical synthesis of 4-hydroxycyclophosphamide CTD PMID:24819615 CYP2C9 Human 4-hydroxyphenytoin multiple interactions EXP 6480464 [CYP2C9 protein results in increased hydroxylation of Phenytoin] which results in increased abundance of hydroxyphenytoin; more ... CTD PMID:33961833 CYP2C9 Human 4-hydroxytolbutamide increases chemical synthesis EXP 6480464 CYP2C9 protein results in increased chemical synthesis of 4'-hydroxytolbutamide; CYP2C9 protein results in increased chemical more ... CTD PMID:15155557|PMID:21915887 CYP2C9 Human 4-hydroxytolbutamide multiple interactions ISO Cyp2c65 (Mus musculus) 6480464 [CYP2C65 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of more ... CTD PMID:30503582 CYP2C9 Human 4-hydroxytolbutamide multiple interactions EXP 6480464 [CYP2C9 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of more ... CTD PMID:21915887|PMID:32198085 CYP2C9 Human 4-Hydroxyvalproic acid increases chemical synthesis EXP 6480464 CYP2C9 protein results in increased chemical synthesis of 4-hydroxyvalproate CTD PMID:16945988 CYP2C9 Human 4-isopropylphenol increases glutathionylation EXP 6480464 CYP2C9 protein results in increased glutathionylation of 4-isopropylphenol CTD PMID:23470418 CYP2C9 Human 4-methylimidazole multiple interactions EXP 6480464 4-methylimidazole inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac] CTD PMID:16081671 CYP2C9 Human 4-tert-Octylphenol increases response to substance EXP 6480464 CYP2C9 gene SNP results in increased susceptibility to 4-tert-octylphenol CTD PMID:23555028 CYP2C9 Human 5,7-dihydroxy-4'-methoxyflavone multiple interactions EXP 6480464 acacetin inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] CTD PMID:21053930 CYP2C9 Human 5-Hydroxyflavone multiple interactions EXP 6480464 5-hydroxyflavone inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] CTD PMID:21053930 CYP2C9 Human 5-Hydroxyvalproic acid increases chemical synthesis EXP 6480464 CYP2C9 protein results in increased chemical synthesis of 5-hydroxyvalproate CTD PMID:16945988 CYP2C9 Human 5-methoxy-2-\{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl\}-1H-benzimidazole multiple interactions EXP 6480464 Omeprazole inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Diclofenac] CTD PMID:15258107 CYP2C9 Human 5-methoxy-2-\{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl\}-1H-benzimidazole decreases activity ISO Cyp2c65 (Mus musculus) 6480464 Omeprazole results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human 5-methoxyindole decreases activity EXP 6480464 5-methoxyindole results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human 5-methyltryptamine decreases activity EXP 6480464 5-methyltryptamine analog results in decreased activity of CYP2C9 protein CTD PMID:26599973 CYP2C9 Human 5-methyltryptamine multiple interactions EXP 6480464 [5-methyltryptamine analog results in decreased activity of CYP2C9 protein] which results in decreased metabolism of more ... CTD PMID:26599973 CYP2C9 Human 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime increases expression EXP 6480464 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2C9 mRNA CTD PMID:21768169 CYP2C9 Human 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime multiple interactions EXP 6480464 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein co-treated with FOXO1 protein co-treated with HNF4A protein more ... CTD PMID:21768169 CYP2C9 Human 6-hydroxywarfarin decreases activity EXP 6480464 6-hydroxywarfarin results in decreased activity of CYP2C9 protein CTD PMID:20429590 CYP2C9 Human 6-hydroxywarfarin multiple interactions EXP 6480464 6-hydroxywarfarin inhibits the reaction [[CYP2C9 protein results in increased hydroxylation of Warfarin] which results in more ... CTD PMID:19408964|PMID:20429590|PMID:27539372 CYP2C9 Human 7,12-dimethyltetraphene increases response to substance EXP 6480464 CYP2C9 protein results in increased susceptibility to 9,10-Dimethyl-1,2-benzanthracene CTD PMID:20507880 CYP2C9 Human 7-hydroxyflavone multiple interactions EXP 6480464 7-hydroxyflavone inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] CTD PMID:21053930 CYP2C9 Human 7-hydroxyflavone decreases activity EXP 6480464 7-hydroxyflavone results in decreased activity of CYP2C9 protein CTD PMID:29753067 CYP2C9 Human 7-Hydroxywarfarin multiple interactions EXP 6480464 10-hydroxywarfarin inhibits the reaction [[CYP2C9 protein results in increased hydroxylation of Warfarin] which results in more ... CTD PMID:19408964|PMID:20429590|PMID:27539372|PMID:31854189 CYP2C9 Human 7-Hydroxywarfarin decreases activity EXP 6480464 7-hydroxywarfarin results in decreased activity of CYP2C9 protein CTD PMID:20429590 CYP2C9 Human 7-Hydroxywarfarin increases chemical synthesis EXP 6480464 CYP2C9 protein results in increased chemical synthesis of 7-hydroxywarfarin CTD PMID:25986145 CYP2C9 Human 7-Hydroxywarfarin affects abundance EXP 6480464 CYP2C9 gene polymorphism affects the abundance of 7-hydroxywarfarin CTD PMID:25986145 CYP2C9 Human 8'-apo-beta,psi-caroten-8'-al increases expression EXP 6480464 apocarotenal results in increased expression of CYP2C9 mRNA CTD PMID:17034753 CYP2C9 Human 8,9-EET increases chemical synthesis EXP 6480464 CYP2C9 protein results in increased chemical synthesis of 8,9-epoxyeicosatrienoic acid CTD PMID:12675279 CYP2C9 Human 8,9-EET multiple interactions EXP 6480464 Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased chemical synthesis of 8,9-epoxyeicosatrienoic acid] CTD PMID:12675279 CYP2C9 Human AB-Fubinaca decreases activity EXP 6480464 AB-FUBINACA results in decreased activity of CYP2C9 protein CTD PMID:33050066 CYP2C9 Human acenaphthylene increases oxidation EXP 6480464 CYP2C9 protein results in increased oxidation of acenaphthylene CTD PMID:25642975 CYP2C9 Human acenocoumarol affects metabolic processing EXP 6480464 CYP2C9 protein affects the metabolism of Acenocoumarol CTD PMID:11918509 CYP2C9 Human acenocoumarol affects response to substance EXP 6480464 CYP2C9 gene polymorphism affects the susceptibility to Acenocoumarol; CYP2C9 gene SNP affects the susceptibility to more ... CTD PMID:15213846|PMID:16869821|PMID:16878445|PMID:18021343|PMID:18698879|PMID:19578179|PMID:28867752 CYP2C9 Human acenocoumarol increases response to substance EXP 6480464 CYP2C9 protein results in increased susceptibility to Acenocoumarol CTD PMID:16869821 CYP2C9 Human acenocoumarol increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of Acenocoumarol CTD PMID:16878445 CYP2C9 Human acetone multiple interactions EXP 6480464 Acetone promotes the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide] CTD PMID:10611138 CYP2C9 Human acetonitrile multiple interactions EXP 6480464 acetonitrile promotes the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide] CTD PMID:10611138 CYP2C9 Human acetylsalicylic acid affects response to substance EXP 6480464 CYP2C9 polymorphism affects the susceptibility to Aspirin CTD PMID:21966608 CYP2C9 Human aconitine increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of Aconitine CTD PMID:21277363 CYP2C9 Human aconitine multiple interactions EXP 6480464 [Amiodarone results in decreased activity of CYP2C9 protein] which results in decreased chemical synthesis of more ... CTD PMID:21277363 CYP2C9 Human adefovir decreases activity EXP 6480464 adefovir results in decreased activity of CYP2C9 protein CTD PMID:17162464 CYP2C9 Human adefovir pivoxil decreases activity EXP 6480464 adefovir dipivoxil results in decreased activity of CYP2C9 protein CTD PMID:17162464 CYP2C9 Human afimoxifene increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of afimoxifene CTD PMID:29285606 CYP2C9 Human aflatoxin B1 affects expression EXP 6480464 Aflatoxin B1 affects the expression of CYP2C9 protein CTD PMID:20106945 CYP2C9 Human aflatoxin B1 decreases methylation EXP 6480464 Aflatoxin B1 results in decreased methylation of CYP2C9 gene CTD PMID:27153756 CYP2C9 Human aflatoxin B1 decreases expression EXP 6480464 Aflatoxin B1 results in decreased expression of CYP2C9 mRNA CTD PMID:27153756 CYP2C9 Human aflatoxin B1 multiple interactions EXP 6480464 [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated more ... CTD PMID:23397584 CYP2C9 Human aflatoxin B1 increases expression EXP 6480464 Aflatoxin B1 results in increased expression of CYP2C9 mRNA CTD PMID:21994236 CYP2C9 Human alizarin decreases activity EXP 6480464 alizarin results in decreased activity of CYP2C9 protein CTD PMID:33438235 CYP2C9 Human all-trans-4-hydroxyretinoic acid increases chemical synthesis EXP 6480464 CYP2C9 protein results in increased chemical synthesis of 4-hydroxyretinoic acid CTD PMID:10874126 CYP2C9 Human all-trans-4-oxoretinoic acid increases chemical synthesis EXP 6480464 CYP2C9 protein results in increased chemical synthesis of 4-oxoretinoic acid CTD PMID:10874126 CYP2C9 Human all-trans-retinoic acid decreases expression EXP 6480464 Tretinoin results in decreased expression of CYP2C9 mRNA CTD PMID:16985168 CYP2C9 Human all-trans-retinoic acid increases hydroxylation EXP 6480464 CYP2C9 protein results in increased hydroxylation of Tretinoin CTD PMID:10874126 CYP2C9 Human all-trans-retinoic acid decreases activity EXP 6480464 Tretinoin results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human Aloe emodin decreases activity EXP 6480464 aloe emodin results in decreased activity of CYP2C9 protein CTD PMID:33438235 CYP2C9 Human alpha-linolenic acid decreases activity EXP 6480464 alpha-Linolenic Acid results in decreased activity of CYP2C9 protein CTD PMID:16978661 CYP2C9 Human alpha-linolenic acid multiple interactions EXP 6480464 CYP2C9 protein results in increased metabolism of [alpha-Linolenic Acid co-treated with NADP] CTD PMID:16978661 CYP2C9 Human alpha-naphthoflavone multiple interactions EXP 6480464 alpha-naphthoflavone inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] CTD PMID:21053930 CYP2C9 Human amiodarone multiple interactions EXP 6480464 [Amiodarone results in decreased activity of CYP2C9 protein] which results in decreased chemical synthesis of more ... CTD PMID:14557374|PMID:16081671|PMID:21277363 CYP2C9 Human amiodarone increases expression EXP 6480464 Amiodarone results in increased expression of CYP2C9 mRNA CTD PMID:36586010 CYP2C9 Human amiodarone decreases response to substance EXP 6480464 CYP2C9 protein results in decreased susceptibility to Amiodarone CTD PMID:26477383 CYP2C9 Human amiodarone decreases activity EXP 6480464 Amiodarone results in decreased activity of CYP2C9 protein CTD PMID:16449812 CYP2C9 Human amitriptyline multiple interactions EXP 6480464 [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated more ... CTD PMID:23397584 CYP2C9 Human amodiaquine decreases activity EXP 6480464 Amodiaquine results in decreased activity of CYP2C9 protein CTD PMID:11124226 CYP2C9 Human Ancriviroc affects metabolic processing EXP 6480464 CYP2C9 protein affects the metabolism of Ancriviroc CTD PMID:16012074 CYP2C9 Human Ancriviroc decreases ethylation EXP 6480464 CYP2C9 protein results in decreased ethylation of Ancriviroc CTD PMID:16012074 CYP2C9 Human andrographolide decreases expression EXP 6480464 andrographolide results in decreased expression of CYP2C9 mRNA CTD PMID:19041297 CYP2C9 Human anthra[1,9-cd]pyrazol-6(2H)-one multiple interactions EXP 6480464 pyrazolanthrone inhibits the reaction [2-tert-butylhydroquinone results in increased expression of CYP2C9 mRNA] CTD PMID:24830941 CYP2C9 Human anthracene-1,8,9-triol decreases activity EXP 6480464 Anthralin results in decreased activity of CYP2C9 protein CTD PMID:33438235 CYP2C9 Human apigenin multiple interactions EXP 6480464 Apigenin inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] CTD PMID:21053930 CYP2C9 Human apigenin decreases activity EXP 6480464 Apigenin results in decreased activity of CYP2C9 protein CTD PMID:29753067 CYP2C9 Human arachidonic acid increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of Arachidonic Acid CTD PMID:12675279 CYP2C9 Human arachidonic acid decreases activity EXP 6480464 Arachidonic Acid results in decreased activity of CYP2C9 protein CTD PMID:16978661 CYP2C9 Human arachidonic acid multiple interactions EXP 6480464 CYP2C9 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP]; Sulfaphenazole inhibits the more ... CTD PMID:12675279|PMID:16978661 CYP2C9 Human aristolochic acid A increases expression EXP 6480464 aristolochic acid I results in increased expression of CYP2C9 mRNA CTD PMID:33212167 CYP2C9 Human atazanavir sulfate multiple interactions EXP 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated more ... CTD PMID:33819548 CYP2C9 Human Auriculasin multiple interactions EXP 6480464 Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased metabolism of auriculasin] CTD PMID:31515991 CYP2C9 Human Auriculasin decreases activity EXP 6480464 auriculasin results in decreased activity of CYP2C9 protein CTD PMID:31515991 CYP2C9 Human Auriculasin increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of auriculasin CTD PMID:31515991 CYP2C9 Human Avasimibe decreases activity EXP 6480464 avasimibe results in decreased activity of CYP2C9 protein CTD PMID:15333513 CYP2C9 Human Avasimibe multiple interactions EXP 6480464 avasimibe results in increased activity of and results in increased expression of CYP2C9 protein; avasimibe more ... CTD PMID:15333513|PMID:19202563 CYP2C9 Human Azoxymethane multiple interactions ISO Cyp2c65 (Mus musculus) 6480464 [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C65 more ... CTD PMID:29950665 CYP2C9 Human baicalein multiple interactions EXP 6480464 baicalein inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] CTD PMID:21053930 CYP2C9 Human baicalein decreases activity EXP 6480464 baicalein results in decreased activity of CYP2C9 protein CTD PMID:29753067 CYP2C9 Human barnidipine decreases activity EXP 6480464 mepirodipine results in decreased activity of CYP2C9 protein CTD PMID:10805063 CYP2C9 Human benfuracarb increases oxidation EXP 6480464 CYP2C9 protein results in increased oxidation of benfuracarb CTD PMID:24016712 CYP2C9 Human benidipine decreases activity EXP 6480464 benidipine results in decreased activity of CYP2C9 protein CTD PMID:10805063|PMID:27732883 CYP2C9 Human benzbromarone multiple interactions EXP 6480464 Benzbromarone analog binds to and results in decreased activity of CYP2C9 protein; Benzbromarone binds to more ... CTD PMID:10613612|PMID:12814975|PMID:15170332|PMID:15955872|PMID:16081671 CYP2C9 Human benzbromarone affects metabolic processing EXP 6480464 CYP2C9 protein affects the metabolism of Benzbromarone CTD PMID:18020424|PMID:21321060 CYP2C9 Human benzbromarone affects binding EXP 6480464 Benzbromarone binds to CYP2C9 protein CTD PMID:12814975 CYP2C9 Human benzo[a]pyrene decreases expression EXP 6480464 Benzo(a)pyrene results in decreased expression of CYP2C9 mRNA CTD PMID:32234424 CYP2C9 Human beta-carotene increases expression EXP 6480464 beta Carotene results in increased expression of CYP2C9 mRNA CTD PMID:17034753 CYP2C9 Human beta-naphthoflavone multiple interactions EXP 6480464 beta-Naphthoflavone inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] CTD PMID:21053930 CYP2C9 Human beta-naphthoflavone decreases expression EXP 6480464 beta-Naphthoflavone results in decreased expression of CYP2C9 mRNA CTD PMID:16985168|PMID:33263786 CYP2C9 Human bilirubin IXalpha increases expression EXP 6480464 Bilirubin results in increased expression of CYP2C9 mRNA CTD PMID:15382119 CYP2C9 Human bilirubin IXalpha multiple interactions EXP 6480464 IL1B protein inhibits the reaction [Bilirubin results in increased expression of CYP2C9 mRNA] CTD PMID:15382119 CYP2C9 Human biochanin A decreases activity EXP 6480464 biochanin A results in decreased activity of CYP2C9 protein CTD PMID:26278343 CYP2C9 Human bis(2-ethylhexyl) phthalate increases expression ISO Cyp2c65 (Mus musculus) 6480464 Diethylhexyl Phthalate results in increased expression of CYP2C9 mRNA CTD PMID:39109301 CYP2C9 Human bisphenol A increases hydroxylation EXP 6480464 CYP2C9 protein results in increased hydroxylation of bisphenol A; CYP2C9 protein results in increased hydroxylation more ... CTD PMID:23470418 CYP2C9 Human bisphenol A multiple interactions EXP 6480464 [ESR1 protein co-treated with MED25 protein co-treated with bisphenol A] results in increased activity of more ... CTD PMID:27273787 CYP2C9 Human bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of CYP2C9 mRNA CTD PMID:26196221 CYP2C9 Human bisphenol A increases glutathionylation EXP 6480464 CYP2C9 protein results in increased glutathionylation of bisphenol A; CYP2C9 protein results in increased glutathionylation more ... CTD PMID:23470418 CYP2C9 Human bisphenol AF increases hydroxylation EXP 6480464 CYP2C9 protein results in increased hydroxylation of bisphenol AF CTD PMID:23470418 CYP2C9 Human bisphenol F increases glutathionylation EXP 6480464 CYP2C9 protein results in increased glutathionylation of 4,4'-bisphenol F; CYP2C9 protein results in increased glutathionylation more ... CTD PMID:23470418 CYP2C9 Human bisphenol F increases hydroxylation EXP 6480464 CYP2C9 protein results in increased hydroxylation of 4,4'-bisphenol F CTD PMID:23470418 CYP2C9 Human bortezomib affects metabolic processing EXP 6480464 CYP2C9 protein affects the metabolism of Bortezomib CTD PMID:15764713 CYP2C9 Human brequinar increases expression EXP 6480464 brequinar results in increased expression of CYP2C9 mRNA CTD PMID:39900124 CYP2C9 Human bromfenac multiple interactions EXP 6480464 Acetylcysteine affects the reaction [CYP2C9 protein results in increased hydroxylation of bromfenac]; Glutathione affects the more ... CTD PMID:31815452 CYP2C9 Human bromfenac increases hydroxylation EXP 6480464 CYP2C9 protein results in increased hydroxylation of bromfenac CTD PMID:31815452 CYP2C9 Human Bufuralol increases hydroxylation EXP 6480464 CYP2C9 protein results in increased hydroxylation of bufuralol CTD PMID:9429232 CYP2C9 Human busulfan multiple interactions EXP 6480464 [GSTM1 protein co-treated with CYP2C9 protein] results in increased susceptibility to [Busulfan co-treated with Cyclophosphamide] CTD PMID:28744217 CYP2C9 Human butanal increases expression EXP 6480464 butyraldehyde results in increased expression of CYP2C9 mRNA CTD PMID:26079696 CYP2C9 Human butyric acid multiple interactions EXP 6480464 [Butyric Acid co-treated with Sulfaphenazole] inhibits the reaction [Oxalic Acid results in increased expression of more ... CTD PMID:37414240 CYP2C9 Human C.I. Natural Red 20 decreases activity EXP 6480464 shikonin results in decreased activity of CYP2C9 protein CTD PMID:28941798 CYP2C9 Human cadmium atom increases expression EXP 6480464 Cadmium results in increased expression of CYP2C9 protein CTD PMID:11551516 CYP2C9 Human caffeine decreases activity ISO Cyp2c65 (Mus musculus) 6480464 Caffeine results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human calciol increases expression EXP 6480464 Cholecalciferol metabolite results in increased expression of CYP2C9 CTD PMID:11991950 CYP2C9 Human calciol decreases activity EXP 6480464 Cholecalciferol results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human cannabidiol decreases activity EXP 6480464 Cannabidiol results in decreased activity of CYP2C9 protein CTD PMID:24667653|PMID:39233107 CYP2C9 Human cannabidiol multiple interactions ISO Cyp2c65 (Mus musculus) 6480464 [Plant Extracts results in increased abundance of Cannabidiol] which results in increased expression of CYP2C65 more ... CTD PMID:33096940 CYP2C9 Human capsaicin decreases activity EXP 6480464 Capsaicin results in decreased activity of CYP2C9 protein CTD PMID:22375877 CYP2C9 Human captan increases expression ISO Cyp2c65 (Mus musculus) 6480464 Captan results in increased expression of CYP2C65 mRNA CTD PMID:31558096 CYP2C9 Human carbamazepine increases expression EXP 6480464 Carbamazepine results in increased expression of CYP2C9 mRNA CTD PMID:17112801 CYP2C9 Human carbamazepine multiple interactions EXP 6480464 [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated more ... CTD PMID:23397584 CYP2C9 Human carbamazepine increases activity EXP 6480464 Carbamazepine results in increased activity of CYP2C9 protein CTD PMID:19202563 CYP2C9 Human carbamazepine affects metabolic processing EXP 6480464 CYP2C9 protein affects the metabolism of Carbamazepine CTD PMID:15286053 CYP2C9 Human carfentanil increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of carfentanil CTD PMID:33652071 CYP2C9 Human carnosic acid decreases expression ISO Cyp2c65 (Mus musculus) 6480464 salvin results in decreased expression of CYP2C65 protein CTD PMID:35926579 CYP2C9 Human Carnosol decreases activity EXP 6480464 carnosol results in decreased activity of CYP2C9 protein CTD PMID:34592323 CYP2C9 Human celecoxib increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of Celecoxib CTD PMID:17681167|PMID:19082874 CYP2C9 Human CGP 52608 multiple interactions EXP 6480464 CGP 52608 promotes the reaction [RORA protein binds to CYP2C9 gene] CTD PMID:28238834 CYP2C9 Human chenodeoxycholic acid multiple interactions EXP 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated more ... CTD PMID:33819548|PMID:34589561 CYP2C9 Human chlorotoluron decreases expression EXP 6480464 chlortoluron results in decreased expression of CYP2C9 mRNA CTD PMID:39207506 CYP2C9 Human chlorpromazine decreases activity EXP 6480464 Chlorpromazine results in decreased activity of CYP2C9 protein CTD PMID:15135088 CYP2C9 Human chlorpromazine decreases response to substance EXP 6480464 CYP2C9 protein results in decreased susceptibility to Chlorpromazine CTD PMID:26477383 CYP2C9 Human chlorpromazine multiple interactions EXP 6480464 [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated more ... CTD PMID:23397584 CYP2C9 Human chlorpyrifos affects metabolic processing EXP 6480464 CYP2C9 protein affects the metabolism of Chlorpyrifos CTD PMID:16190164 CYP2C9 Human cholesterol decreases activity ISO Cyp2c65 (Mus musculus) 6480464 Cholesterol results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human choline multiple interactions ISO Cyp2c65 (Mus musculus) 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression more ... CTD PMID:20938992 CYP2C9 Human chrysin multiple interactions EXP 6480464 chrysin inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] CTD PMID:21053930 CYP2C9 Human chrysophanol decreases activity EXP 6480464 chrysophanic acid results in decreased activity of CYP2C9 protein CTD PMID:27633141 CYP2C9 Human cimetidine multiple interactions EXP 6480464 styrofoam analog promotes the reaction [Cimetidine results in decreased activity of CYP2C9 protein] CTD PMID:19909766 CYP2C9 Human cimetidine decreases activity EXP 6480464 Cimetidine results in decreased activity of CYP2C9 protein CTD PMID:19909766 CYP2C9 Human cisapride decreases activity EXP 6480464 Cisapride results in decreased activity of CYP2C9 protein CTD PMID:15306208 CYP2C9 Human cisplatin affects response to substance EXP 6480464 CYP2C9 protein affects the susceptibility to Cisplatin CTD PMID:16217747 CYP2C9 Human clofibric acid increases expression EXP 6480464 Clofibric Acid results in increased expression of CYP2C9 mRNA CTD PMID:15802389 CYP2C9 Human clopidogrel affects response to substance EXP 6480464 CYP2C9 gene SNP affects the susceptibility to clopidogrel CTD PMID:17900275 CYP2C9 Human clopidogrel decreases metabolic processing EXP 6480464 CYP2C9 gene SNP results in decreased metabolism of clopidogrel CTD PMID:17900275 CYP2C9 Human clopidogrel multiple interactions EXP 6480464 CYP2C9 gene affects the reaction [CYP2C19 gene affects the susceptibility to clopidogrel]; CYP2C9 protein results more ... CTD PMID:19170597|PMID:19926050|PMID:19934793 CYP2C9 Human clothianidin multiple interactions EXP 6480464 [clothianidin co-treated with thiacloprid] results in increased expression of CYP2C9 protein CTD PMID:32201337 CYP2C9 Human clotrimazole multiple interactions EXP 6480464 Clotrimazole inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac]; Clotrimazole results in increased more ... CTD PMID:16081671|PMID:19202563 CYP2C9 Human clotrimazole affects binding EXP 6480464 Clotrimazole binds to CYP2C9 protein; Clotrimazole binds to CYP2C9 protein alternative form CTD PMID:29621561 CYP2C9 Human clozapine multiple interactions EXP 6480464 [Clozapine results in decreased activity of CYP2C9 protein] which results in increased susceptibility to Phenytoin; more ... CTD PMID:17961958|PMID:23397584 CYP2C9 Human clozapine increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of Clozapine CTD PMID:18809730 CYP2C9 Human cocaine decreases expression EXP 6480464 Cocaine results in decreased expression of CYP2C9 mRNA; Cocaine results in decreased expression of CYP2C9 more ... CTD PMID:16188404 CYP2C9 Human copper atom multiple interactions EXP 6480464 [CYP2C9 protein co-treated with Copper] results in increased activity of Eugenol CTD PMID:15576237 CYP2C9 Human copper(0) multiple interactions EXP 6480464 [CYP2C9 protein co-treated with Copper] results in increased activity of Eugenol CTD PMID:15576237 CYP2C9 Human corticosterone increases expression EXP 6480464 Corticosterone results in increased expression of CYP2C9 mRNA CTD PMID:35301062 CYP2C9 Human coumarin affects metabolic processing EXP 6480464 CYP2C9 protein polymorphism affects the metabolism of coumarin CTD PMID:17849045 CYP2C9 Human coumarin affects response to substance EXP 6480464 CYP2C9 protein polymorphism affects the susceptibility to coumarin CTD PMID:23582453 CYP2C9 Human coumarins multiple interactions EXP 6480464 Amiodarone promotes the reaction [CYP2C9 protein results in increased metabolism of Coumarins]; Dichlorphenamide promotes the more ... CTD PMID:14557374 CYP2C9 Human coumarins increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of Coumarins CTD PMID:14557374 CYP2C9 Human cumene hydroperoxide affects oxidation EXP 6480464 CYP2C9 protein affects the oxidation of cumene hydroperoxide CTD PMID:17478480 CYP2C9 Human cyclophosphamide increases response to substance EXP 6480464 CYP2C9 protein results in increased susceptibility to Cyclophosphamide CTD PMID:10991840 CYP2C9 Human cyclophosphamide decreases activity ISO Cyp2c65 (Mus musculus) 6480464 Cyclophosphamide results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human cyclophosphamide increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of Cyclophosphamide CTD PMID:11377097|PMID:24819615 CYP2C9 Human cyclophosphamide multiple interactions EXP 6480464 [GSTM1 protein co-treated with CYP2C9 protein] results in increased susceptibility to [Busulfan co-treated with Cyclophosphamide]; more ... CTD PMID:10991840|PMID:28744217 CYP2C9 Human cyclophosphamide increases activity EXP 6480464 CYP2C9 results in increased activity of Cyclophosphamide CTD PMID:9241661 CYP2C9 Human cyclosporin A decreases expression EXP 6480464 Cyclosporine results in decreased expression of CYP2C9 mRNA CTD PMID:20106945|PMID:27989131 CYP2C9 Human cyclosporin A multiple interactions EXP 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated more ... CTD PMID:33819548 CYP2C9 Human cylindrospermopsin decreases activity EXP 6480464 cylindrospermopsin results in decreased activity of CYP2C9 protein CTD PMID:30905859 CYP2C9 Human cypermethrin increases expression EXP 6480464 cypermethrin results in increased expression of CYP2C9 mRNA CTD PMID:22310298 CYP2C9 Human cypermethrin decreases activity EXP 6480464 cypermethrin results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human cyproconazole increases expression ISO Cyp2c65 (Mus musculus) 6480464 cyproconazole results in increased expression of CYP2C65 mRNA CTD PMID:22334560|PMID:23970803 CYP2C9 Human cyproconazole affects binding EXP 6480464 cyproconazole binds to CYP2C9 protein alternative form CTD PMID:29621561 CYP2C9 Human cyproconazole decreases activity EXP 6480464 cyproconazole results in decreased activity of CYP2C9 protein CTD PMID:21251949 CYP2C9 Human dabrafenib decreases activity EXP 6480464 dabrafenib results in decreased activity of CYP2C9 protein CTD PMID:34780725 CYP2C9 Human daidzein decreases activity EXP 6480464 daidzein results in decreased activity of CYP2C9 protein CTD PMID:18420780|PMID:29753067 CYP2C9 Human dapsone affects metabolic processing EXP 6480464 CYP2C9 protein affects the metabolism of Dapsone CTD PMID:12920490 CYP2C9 Human dapsone decreases activity EXP 6480464 Dapsone results in decreased activity of CYP2C9 protein CTD PMID:11124226 CYP2C9 Human dapsone multiple interactions EXP 6480464 Dapsone promotes the reaction [CYP2C9 protein polymorphism results in decreased methylation of Naproxen]; Dapsone promotes more ... CTD PMID:15130760 CYP2C9 Human delavirdine decreases activity EXP 6480464 Delavirdine results in decreased activity of CYP2C9 protein CTD PMID:11225565 CYP2C9 Human deoxycholic acid multiple interactions EXP 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated more ... CTD PMID:33819548|PMID:34589561 CYP2C9 Human desipramine decreases activity EXP 6480464 Desipramine results in decreased activity of CYP2C9 protein CTD PMID:15135088 CYP2C9 Human dexamethasone multiple interactions EXP 6480464 Dexamethasone results in increased expression of and results in increased activity of CYP2C9 protein CTD PMID:15802389 CYP2C9 Human dexamethasone increases activity EXP 6480464 Dexamethasone results in increased activity of CYP2C9 protein CTD PMID:19202563 CYP2C9 Human dexamethasone increases expression EXP 6480464 Dexamethasone results in increased expression of CYP2C9 mRNA CTD PMID:15802389 CYP2C9 Human dextran sulfate multiple interactions ISO Cyp2c65 (Mus musculus) 6480464 [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C65 more ... CTD PMID:29950665 CYP2C9 Human dextromethorphan decreases activity ISO Cyp2c65 (Mus musculus) 6480464 Dextromethorphan results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human diarylheptanoid decreases activity EXP 6480464 Diarylheptanoids results in decreased activity of CYP2C9 protein CTD PMID:23850985 CYP2C9 Human diazinon multiple interactions EXP 6480464 CYP2C9 protein results in increased metabolism of and results in increased activity of Diazinon CTD PMID:11708902 CYP2C9 Human dibenz[a,h]anthracene multiple interactions EXP 6480464 [CYP2C9 protein results in increased metabolism of 1,2,5,6-dibenzanthracene] which results in increased chemical synthesis of more ... CTD PMID:8638931 CYP2C9 Human dibenz[a,h]anthracene increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of 1,2,5,6-dibenzanthracene CTD PMID:8638931 CYP2C9 Human diclofenac multiple interactions EXP 6480464 1-aminobenzotriazole inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Diclofenac]; 4-methylimidazole inhibits the more ... CTD PMID:12569440|PMID:15258107|PMID:15486075|PMID:15618748|PMID:16049126|PMID:16081671|PMID:20452209|PMID:21964418|PMID:22447115|PMID:23397584|PMID:23721565|PMID:24104198|PMID:24246759|PMID:25084468|PMID:25994031|PMID:26599973|PMID:28119166|PMID:28762043|PMID:29555536|PMID:31854189|PMID:35366062|PMID:35583123|PMID:35748891 CYP2C9 Human diclofenac decreases activity ISO Cyp2c65 (Mus musculus) 6480464 Diclofenac results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human diclofenac increases hydroxylation EXP 6480464 CYP2C9 protein results in increased hydroxylation of Diclofenac CTD PMID:10975605|PMID:10991840|PMID:11455026|PMID:15258107|PMID:15618748|PMID:15860655|PMID:21964418|PMID:25994031|PMID:26255664|PMID:27590069|PMID:29445054|PMID:35583123|PMID:35748891|PMID:9110362|PMID:9241660 CYP2C9 Human diclofenac increases hydrolysis EXP 6480464 CYP2C9 protein results in increased hydrolysis of Diclofenac CTD PMID:9698079 CYP2C9 Human diclofenac affects hydrolysis EXP 6480464 CYP2C9 gene polymorphism affects the hydrolysis of Diclofenac CTD PMID:9698079 CYP2C9 Human diclofenac increases metabolic processing EXP 6480464 CYP2C9 mRNA results in increased metabolism of Diclofenac; CYP2C9 protein results in increased metabolism of more ... CTD PMID:12401345|PMID:12464242|PMID:12569440|PMID:15155557|PMID:16049126|PMID:17418993|PMID:17681167|PMID:17994679|PMID:19082874|PMID:19309152|PMID:20452209|PMID:23721565|PMID:24104198|PMID:25084468|PMID:28119166|PMID:29555536|PMID:33259822|PMID:35366062 CYP2C9 Human diclofenac decreases hydroxylation EXP 6480464 CYP2C9 gene polymorphism results in decreased hydroxylation of Diclofenac CTD PMID:11455026 CYP2C9 Human diclofenac increases activity EXP 6480464 Diclofenac results in increased activity of CYP2C9 protein CTD PMID:15802386 CYP2C9 Human diclofenac decreases activity EXP 6480464 Diclofenac results in decreased activity of CYP2C9 protein CTD PMID:15135088 CYP2C9 Human diclofenac increases oxidation EXP 6480464 CYP2C9 protein results in increased oxidation of Diclofenac CTD PMID:17478480 CYP2C9 Human diclofenac affects binding EXP 6480464 CYP2C9 protein binds to Diclofenac CTD PMID:15039296 CYP2C9 Human diclofenac affects metabolic processing EXP 6480464 CYP2C9 protein affects the metabolism of Diclofenac CTD PMID:15801540|PMID:16081671 CYP2C9 Human diclofenamide multiple interactions EXP 6480464 Dichlorphenamide promotes the reaction [CYP2C9 protein results in increased metabolism of Coumarins] CTD PMID:14557374 CYP2C9 Human dicyclanil increases expression ISO Cyp2c65 (Mus musculus) 6480464 dicyclanil results in increased expression of CYP2C9 mRNA CTD PMID:15664270 CYP2C9 Human difenoconazole affects binding EXP 6480464 difenoconazole binds to CYP2C9 protein; difenoconazole binds to CYP2C9 protein alternative form CTD PMID:29621561 CYP2C9 Human dihydrocapsaicin decreases activity EXP 6480464 dihydrocapsaicin results in decreased activity of CYP2C9 protein CTD PMID:22375877 CYP2C9 Human dihydroergotamine decreases activity EXP 6480464 Dihydroergotamine results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human dimemorfan increases oxidation EXP 6480464 CYP2C9 protein results in increased oxidation of dimemorfan CTD PMID:19593786 CYP2C9 Human dimethyl sulfoxide multiple interactions EXP 6480464 [Dimethyl Sulfoxide co-treated with TGFB1 protein] results in decreased expression of CYP2C9 mRNA; [Dimethyl Sulfoxide more ... CTD PMID:35366062 CYP2C9 Human diniconazole affects binding EXP 6480464 diniconazole binds to CYP2C9 protein alternative form CTD PMID:29621561 CYP2C9 Human dioscin increases expression EXP 6480464 dioscin results in increased expression of CYP2C9 mRNA CTD PMID:29990575 CYP2C9 Human diosmetin decreases activity EXP 6480464 diosmetin results in decreased activity of CYP2C9 protein CTD PMID:28867436 CYP2C9 Human dioxygen decreases expression EXP 6480464 Oxygen deficiency results in decreased expression of CYP2C9 mRNA CTD PMID:19695866 CYP2C9 Human dodecanoic acid decreases hydroxylation EXP 6480464 CYP2C9 gene polymorphism results in decreased hydroxylation of lauric acid CTD PMID:11455026 CYP2C9 Human dodecanoic acid increases hydroxylation EXP 6480464 CYP2C9 protein results in increased hydroxylation of lauric acid CTD PMID:11455026|PMID:9241660 CYP2C9 Human dopamine decreases activity ISO Cyp2c65 (Mus musculus) 6480464 Dopamine results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human econazole multiple interactions EXP 6480464 Econazole binds to and results in decreased activity of CYP2C9 protein; Econazole binds to and more ... CTD PMID:29621561 CYP2C9 Human efavirenz decreases activity EXP 6480464 efavirenz results in decreased activity of CYP2C9 protein CTD PMID:11225565 CYP2C9 Human ellipticine increases metabolic processing EXP 6480464 CYP2C9 protein mutant form results in increased metabolism of ellipticine CTD PMID:22917556 CYP2C9 Human emodin decreases activity EXP 6480464 Emodin results in decreased activity of CYP2C9 protein CTD PMID:27633141|PMID:33438235 CYP2C9 Human enilconazole decreases expression EXP 6480464 enilconazole results in decreased expression of CYP2C9 mRNA CTD PMID:32201337 CYP2C9 Human epoxiconazole increases expression ISO Cyp2c65 (Mus musculus) 6480464 epoxiconazole results in increased expression of CYP2C65 mRNA CTD PMID:22334560|PMID:23970803 CYP2C9 Human erythromycin A decreases activity ISO Cyp2c65 (Mus musculus) 6480464 Erythromycin results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human estropipate multiple interactions EXP 6480464 estropipate promotes the reaction [CYP2C9 protein results in increased metabolism of Coumarins] CTD PMID:14557374 CYP2C9 Human ethanol decreases expression EXP 6480464 Ethanol results in decreased expression of CYP2C9 mRNA CTD PMID:31059573 CYP2C9 Human ethanol increases expression EXP 6480464 Ethanol results in increased expression of CYP2C9 mRNA CTD PMID:35301062 CYP2C9 Human eugenol multiple interactions EXP 6480464 [CYP2C9 protein co-treated with Copper] results in increased activity of Eugenol CTD PMID:15576237 CYP2C9 Human felbamate increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of Felbamate CTD PMID:35786679 CYP2C9 Human felodipine decreases activity EXP 6480464 Felodipine results in decreased activity of CYP2C9 protein CTD PMID:27732883 CYP2C9 Human fenitrothion multiple interactions EXP 6480464 Fenitrothion inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide] CTD PMID:22634058 CYP2C9 Human fenitrothion decreases activity EXP 6480464 Fenitrothion results in decreased activity of CYP2C9 protein CTD PMID:20183062|PMID:22634058 CYP2C9 Human fenvalerate increases expression EXP 6480464 fenvalerate results in increased expression of CYP2C9 mRNA CTD PMID:22310298 CYP2C9 Human fimasartan increases hydroxylation EXP 6480464 CYP2C9 protein results in increased hydroxylation of fimasartan CTD PMID:29596975 CYP2C9 Human fimasartan increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of fimasartan CTD PMID:29596975 CYP2C9 Human fimasartan increases oxidation EXP 6480464 CYP2C9 protein results in increased oxidation of fimasartan CTD PMID:29596975 CYP2C9 Human fipronil increases expression EXP 6480464 fipronil results in increased expression of CYP2C9 mRNA CTD PMID:27091632 CYP2C9 Human fipronil multiple interactions EXP 6480464 [fipronil co-treated with DEET] results in increased expression of CYP2C9 mRNA CTD PMID:27091632 CYP2C9 Human flavanone multiple interactions EXP 6480464 flavanone inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] CTD PMID:21053930 CYP2C9 Human flavone multiple interactions EXP 6480464 flavone inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] CTD PMID:21053930 CYP2C9 Human flavonol multiple interactions EXP 6480464 3-hydroxyflavone inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] CTD PMID:21053930 CYP2C9 Human fluconazole decreases activity EXP 6480464 Fluconazole results in decreased activity of CYP2C9 protein CTD PMID:15328084|PMID:15843491|PMID:26599973 CYP2C9 Human fluconazole multiple interactions EXP 6480464 [Fluconazole results in decreased activity of CYP2C9 protein] which results in decreased metabolism of Diclofenac; more ... CTD PMID:16081671|PMID:18378563|PMID:26599973|PMID:28887089 CYP2C9 Human fluorescein (lactone form) multiple interactions EXP 6480464 [CYP2C9 protein results in increased metabolism of dibenzylfluorescein] which results in increased chemical synthesis of more ... CTD PMID:23850985 CYP2C9 Human fluoxetine affects abundance EXP 6480464 CYP2C9 gene polymorphism affects the abundance of Fluoxetine; CYP2C9 protein affects the abundance of Fluoxetine CTD PMID:14726986|PMID:15094477 CYP2C9 Human fluoxetine increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of Fluoxetine CTD PMID:14726986 CYP2C9 Human fluphenazine decreases activity EXP 6480464 Fluphenazine results in decreased activity of CYP2C9 protein CTD PMID:15135088 CYP2C9 Human flurbiprofen multiple interactions EXP 6480464 3',4'-dimethoxyflavone inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen]; 3-hydroxyflavone inhibits the more ... CTD PMID:15130760|PMID:15955872|PMID:18378563|PMID:21053930 CYP2C9 Human flurbiprofen affects metabolic processing EXP 6480464 CYP2C9 gene polymorphism affects the metabolism of Flurbiprofen CTD PMID:11901091|PMID:18378563|PMID:25775139 CYP2C9 Human flurbiprofen affects hydrolysis EXP 6480464 CYP2C9 gene polymorphism affects the hydrolysis of Flurbiprofen CTD PMID:9698079 CYP2C9 Human flurbiprofen increases hydrolysis EXP 6480464 CYP2C9 protein results in increased hydrolysis of Flurbiprofen CTD PMID:9698079 CYP2C9 Human flurbiprofen increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of Flurbiprofen CTD PMID:11901091|PMID:18378563|PMID:19082874 CYP2C9 Human flurbiprofen increases hydroxylation EXP 6480464 CYP2C9 protein polymorphism results in increased hydroxylation of Flurbiprofen; CYP2C9 protein results in increased hydroxylation more ... CTD PMID:15130760|PMID:21053930 CYP2C9 Human flurbiprofen affects binding EXP 6480464 Flurbiprofen binds to CYP2C9 protein CTD PMID:21053930 CYP2C9 Human flurbiprofen affects hydroxylation EXP 6480464 CYP2C9 protein affects the hydroxylation of Flurbiprofen CTD PMID:15955872 CYP2C9 Human flutamide multiple interactions EXP 6480464 [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated more ... CTD PMID:23397584 CYP2C9 Human flutriafol multiple interactions EXP 6480464 Acetylcysteine inhibits the reaction [flutriafol results in increased expression of CYP2C9 mRNA] CTD PMID:34200939 CYP2C9 Human flutriafol increases expression EXP 6480464 flutriafol results in increased expression of CYP2C9 mRNA CTD PMID:34200939 CYP2C9 Human fluvastatin multiple interactions EXP 6480464 fluvastatin inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac] CTD PMID:16081671 CYP2C9 Human folic acid multiple interactions ISO Cyp2c65 (Mus musculus) 6480464 [1,2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of CYP2C65 mRNA; [Methionine deficiency co-treated more ... CTD PMID:20938992|PMID:22206623 CYP2C9 Human folpet increases expression ISO Cyp2c65 (Mus musculus) 6480464 folpet results in increased expression of CYP2C65 mRNA CTD PMID:31558096 CYP2C9 Human galangin multiple interactions EXP 6480464 galangin inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] CTD PMID:21053930 CYP2C9 Human genistein multiple interactions EXP 6480464 Genistein inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] CTD PMID:21053930 CYP2C9 Human genistein decreases activity EXP 6480464 Genistein results in decreased activity of CYP2C9 protein CTD PMID:29753067 CYP2C9 Human glipizide increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of Glipizide CTD PMID:10208645 CYP2C9 Human glipizide decreases metabolic processing EXP 6480464 CYP2C9 gene polymorphism results in decreased metabolism of Glipizide CTD PMID:10208645 CYP2C9 Human glutathione multiple interactions EXP 6480464 [[CYP2C9 protein co-treated with GSTP1 protein co-treated with Glutathione] results in increased hydroxylation of Diclofenac] more ... CTD PMID:24246759|PMID:31815452|PMID:32198085 CYP2C9 Human glycochenodeoxycholic acid multiple interactions EXP 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated more ... CTD PMID:33819548|PMID:34589561 CYP2C9 Human glycocholic acid multiple interactions EXP 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated more ... CTD PMID:33819548|PMID:34589561 CYP2C9 Human glycodeoxycholic acid multiple interactions EXP 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated more ... CTD PMID:33819548|PMID:34589561 CYP2C9 Human glyphosate decreases activity EXP 6480464 Glyphosate results in decreased activity of CYP2C9 protein CTD PMID:20183062 CYP2C9 Human hesperetin decreases activity EXP 6480464 hesperetin results in decreased activity of CYP2C9 protein CTD PMID:29753067 CYP2C9 Human HET0016 decreases activity EXP 6480464 HET0016 results in decreased activity of CYP2C9 protein CTD PMID:11375247 CYP2C9 Human hydrogen peroxide increases abundance EXP 6480464 CYP2C9 protein results in increased abundance of Hydrogen Peroxide CTD PMID:25061110 CYP2C9 Human hyperforin multiple interactions EXP 6480464 hyperforin results in increased expression of and results in increased activity of CYP2C9 protein; NR1I2 more ... CTD PMID:14600250|PMID:15100173 CYP2C9 Human hyperforin increases expression EXP 6480464 hyperforin results in increased expression of CYP2C9 mRNA CTD PMID:14600250|PMID:15100173|PMID:24259679 CYP2C9 Human ibuprofen affects binding EXP 6480464 CYP2C9 protein binds to Ibuprofen CTD PMID:15039296 CYP2C9 Human ibuprofen affects response to substance EXP 6480464 CYP2C9 protein affects the susceptibility to Ibuprofen CTD PMID:25578229 CYP2C9 Human ibuprofen decreases metabolic processing EXP 6480464 CYP2C9 gene polymorphism results in decreased metabolism of Ibuprofen CTD PMID:15289789|PMID:18694831 CYP2C9 Human ibuprofen multiple interactions EXP 6480464 Ibuprofen inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac] CTD PMID:16081671 CYP2C9 Human ibuprofen increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of Ibuprofen CTD PMID:12464242|PMID:17681167 CYP2C9 Human ibuprofen affects metabolic processing EXP 6480464 CYP2C9 polymorphism affects the metabolism of Ibuprofen; CYP2C9 protein polymorphism affects the metabolism of Ibuprofen CTD PMID:12152005|PMID:37406757 CYP2C9 Human Icaritin decreases activity EXP 6480464 icaritin results in decreased activity of CYP2C9 protein CTD PMID:29753067 CYP2C9 Human ifosfamide increases response to substance EXP 6480464 CYP2C9 protein results in increased susceptibility to Ifosfamide CTD PMID:20507880 CYP2C9 Human ifosfamide increases activity EXP 6480464 CYP2C9 results in increased activity of Ifosfamide CTD PMID:9241661 CYP2C9 Human inulin multiple interactions ISO Cyp2c65 (Mus musculus) 6480464 [perfluorooctane sulfonic acid co-treated with Inulin] results in increased expression of CYP2C65 mRNA CTD PMID:36331819 CYP2C9 Human irbesartan increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of irbesartan CTD PMID:12359989 CYP2C9 Human irbesartan decreases response to substance EXP 6480464 CYP2C9 gene polymorphism results in decreased susceptibility to irbesartan CTD PMID:12359989 CYP2C9 Human irinotecan decreases activity EXP 6480464 Irinotecan metabolite results in decreased activity of CYP2C9 protein CTD PMID:11901092 CYP2C9 Human isocarbophos multiple interactions EXP 6480464 CYP2C9 protein results in increased metabolism of and results in decreased sulfation of and affects more ... CTD PMID:24752505 CYP2C9 Human isoliquiritigenin decreases activity EXP 6480464 isoliquiritigenin results in decreased activity of CYP2C9 protein CTD PMID:29753067 CYP2C9 Human isoproturon decreases activity EXP 6480464 isoproturon results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human Isradipine decreases activity EXP 6480464 Isradipine results in decreased activity of CYP2C9 protein CTD PMID:27732883 CYP2C9 Human ivermectin decreases activity EXP 6480464 Ivermectin results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human kaempferol multiple interactions EXP 6480464 kaempferol inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] CTD PMID:21053930 CYP2C9 Human kaempferol decreases activity EXP 6480464 kaempferol results in decreased activity of CYP2C9 protein CTD PMID:29753067 CYP2C9 Human ketoconazole multiple interactions EXP 6480464 Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with more ... CTD PMID:16081671|PMID:16608920|PMID:24120545 CYP2C9 Human ketoconazole decreases activity ISO Cyp2c65 (Mus musculus) 6480464 Ketoconazole results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human ketoconazole affects binding EXP 6480464 Ketoconazole binds to CYP2C9 protein; Ketoconazole binds to CYP2C9 protein alternative form CTD PMID:29621561 CYP2C9 Human ketoconazole decreases expression EXP 6480464 Ketoconazole results in decreased expression of CYP2C9 mRNA CTD PMID:16608920 CYP2C9 Human ketoconazole decreases activity EXP 6480464 Ketoconazole results in decreased activity of CYP2C9 protein CTD PMID:14709627|PMID:15618748 CYP2C9 Human L-methionine multiple interactions ISO Cyp2c65 (Mus musculus) 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression more ... CTD PMID:20938992 CYP2C9 Human lansoprazole increases hydroxylation EXP 6480464 CYP2C9 protein results in increased hydroxylation of Lansoprazole CTD PMID:12975331|PMID:8627562 CYP2C9 Human lansoprazole multiple interactions EXP 6480464 Lansoprazole inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Diclofenac] CTD PMID:15258107 CYP2C9 Human lead(0) decreases expression EXP 6480464 Lead results in decreased expression of CYP2C9 mRNA CTD PMID:19921347 CYP2C9 Human leflunomide increases expression EXP 6480464 Leflunomide results in increased expression of CYP2C9 mRNA CTD PMID:30364229 CYP2C9 Human Licochalcone A decreases activity EXP 6480464 licochalcone A results in decreased activity of CYP2C9 protein CTD PMID:26100226 CYP2C9 Human linoleic acid multiple interactions EXP 6480464 CYP2C9 protein results in increased metabolism of [Linoleic Acid co-treated with NADP] CTD PMID:16978661 CYP2C9 Human linoleic acid decreases activity EXP 6480464 Linoleic Acid results in decreased activity of CYP2C9 protein CTD PMID:16978661 CYP2C9 Human lipoic acid multiple interactions EXP 6480464 Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated more ... CTD PMID:24120545 CYP2C9 Human liquiritigenin decreases activity EXP 6480464 liquiritigenin results in decreased activity of CYP2C9 protein CTD PMID:29753067 CYP2C9 Human lithocholic acid decreases activity ISO Cyp2c65 (Mus musculus) 6480464 Lithocholic Acid results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human losartan affects metabolic processing EXP 6480464 CYP2C9 protein affects the metabolism of Losartan CTD PMID:20405111|PMID:21321060 CYP2C9 Human losartan increases hydroxylation EXP 6480464 CYP2C9 protein results in increased hydroxylation of Losartan CTD PMID:25994031 CYP2C9 Human losartan multiple interactions EXP 6480464 CYP2C9 gene mutant form inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Losartan]; more ... CTD PMID:20716633|PMID:25994031 CYP2C9 Human losartan increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of Losartan CTD PMID:19082874|PMID:19715737|PMID:20716633 CYP2C9 Human luteolin decreases activity EXP 6480464 Luteolin results in decreased activity of CYP2C9 protein CTD PMID:29753067 CYP2C9 Human Luteolin 7-methyl ether decreases activity EXP 6480464 hydroxygenkwanin results in decreased activity of CYP2C9 protein CTD PMID:34843882 CYP2C9 Human malathion multiple interactions EXP 6480464 Malathion inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide] CTD PMID:22634058 CYP2C9 Human malathion decreases activity EXP 6480464 Malathion results in decreased activity of CYP2C9 protein CTD PMID:20183062|PMID:22634058 CYP2C9 Human mangiferin decreases activity EXP 6480464 mangiferin results in decreased activity of CYP2C9 protein CTD PMID:22815239 CYP2C9 Human manidipine decreases activity EXP 6480464 manidipine results in decreased activity of CYP2C9 protein CTD PMID:10805063 CYP2C9 Human Marrubiin increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of marrubiin CTD PMID:34431289 CYP2C9 Human mefenamic acid increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of Mefenamic Acid CTD PMID:12464242 CYP2C9 Human mefenamic acid increases oxidation EXP 6480464 CYP2C9 protein results in increased oxidation of Mefenamic Acid CTD PMID:33259822 CYP2C9 Human mefenamic acid increases hydroxylation EXP 6480464 CYP2C9 protein results in increased hydroxylation of Mefenamic Acid CTD PMID:25372302 CYP2C9 Human mefenamic acid increases glutathionylation EXP 6480464 CYP2C9 protein results in increased glutathionylation of Mefenamic Acid analog CTD PMID:25372302 CYP2C9 Human Melarsoprol decreases activity EXP 6480464 Melarsoprol results in decreased activity of CYP2C9 protein CTD PMID:11124226 CYP2C9 Human mephenytoin decreases activity ISO Cyp2c65 (Mus musculus) 6480464 Mephenytoin results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human methotrexate decreases expression EXP 6480464 Methotrexate results in decreased expression of CYP2C9 mRNA CTD PMID:24449571 CYP2C9 Human methoxsalen decreases activity EXP 6480464 Methoxsalen results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human methoxychlor multiple interactions EXP 6480464 [CYP2C19 protein co-treated with CYP2C9 protein] results in decreased methylation of Methoxychlor CTD PMID:15486075 CYP2C9 Human methoxychlor decreases activity EXP 6480464 Methoxychlor results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human methoxychlor decreases methylation EXP 6480464 CYP2C9 protein results in decreased methylation of Methoxychlor CTD PMID:12167570|PMID:9733665 CYP2C9 Human Methysticin multiple interactions EXP 6480464 methysticin inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Diclofenac]; NADP promotes the more ... CTD PMID:35583123 CYP2C9 Human Methysticin decreases activity EXP 6480464 methysticin results in decreased activity of CYP2C9 protein CTD PMID:35583123 CYP2C9 Human miconazole multiple interactions EXP 6480464 Miconazole inhibits the reaction [[CYP2C9 protein results in increased hydroxylation of Phenytoin] which results in more ... CTD PMID:16081671|PMID:33961833 CYP2C9 Human miconazole affects binding EXP 6480464 Miconazole binds to CYP2C9 protein; Miconazole binds to CYP2C9 protein alternative form CTD PMID:29621561 CYP2C9 Human miconazole decreases activity EXP 6480464 Miconazole results in decreased activity of CYP2C9 protein CTD PMID:15328084 CYP2C9 Human midazolam decreases activity ISO Cyp2c65 (Mus musculus) 6480464 Midazolam results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human mono(2-ethyl-5-hydroxyhexyl) phthalate multiple interactions EXP 6480464 [CYP2C9 protein polymorphism results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis more ... CTD PMID:22186153|PMID:23545481 CYP2C9 Human mono(2-ethyl-5-oxohexyl) phthalate multiple interactions EXP 6480464 [CYP2C9 protein polymorphism results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis more ... CTD PMID:22186153|PMID:23545481 CYP2C9 Human mono(2-ethylhexyl) phthalate increases metabolic processing EXP 6480464 CYP2C9 protein polymorphism results in increased metabolism of mono-(2-ethylhexyl)phthalate; CYP2C9 protein results in increased metabolism more ... CTD PMID:22186153|PMID:23545481 CYP2C9 Human mono(2-ethylhexyl) phthalate multiple interactions EXP 6480464 [CYP2C9 protein polymorphism results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis more ... CTD PMID:22186153|PMID:23545481 CYP2C9 Human mono(5-carboxy-2-ethylpentyl) phthalate multiple interactions EXP 6480464 [CYP2C9 protein polymorphism results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis more ... CTD PMID:23545481 CYP2C9 Human monosodium L-glutamate multiple interactions ISO Cyp2c65 (Mus musculus) 6480464 [Sodium Glutamate co-treated with Tea] affects the expression of CYP2C9 mRNA CTD PMID:25663641 CYP2C9 Human myricetin decreases activity EXP 6480464 myricetin results in decreased activity of CYP2C9 protein CTD PMID:29753067 CYP2C9 Human N,N-diethyl-m-toluamide increases expression EXP 6480464 DEET results in increased expression of CYP2C9 mRNA CTD PMID:27091632 CYP2C9 Human N,N-diethyl-m-toluamide multiple interactions EXP 6480464 [fipronil co-treated with DEET] results in increased expression of CYP2C9 mRNA CTD PMID:27091632 CYP2C9 Human N-acetyl-L-cysteine multiple interactions EXP 6480464 Acetylcysteine affects the reaction [CYP2C9 protein results in increased hydroxylation of bromfenac]; Acetylcysteine inhibits the more ... CTD PMID:31815452|PMID:34200939 CYP2C9 Human N-desmethylclozapine increases chemical synthesis EXP 6480464 CYP2C9 protein results in increased chemical synthesis of norclozapine CTD PMID:18809730 CYP2C9 Human NADP zwitterion multiple interactions EXP 6480464 [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with more ... CTD PMID:16978661|PMID:24120545|PMID:35583123 CYP2C9 Human NADP(+) multiple interactions EXP 6480464 [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with more ... CTD PMID:16978661|PMID:24120545|PMID:35583123 CYP2C9 Human naphthalene increases expression EXP 6480464 naphthalene results in increased expression of CYP2C9 mRNA CTD PMID:20500019 CYP2C9 Human naproxen multiple interactions EXP 6480464 Amiodarone promotes the reaction [CYP2C9 protein affects the metabolism of Naproxen]; Benzbromarone promotes the reaction more ... CTD PMID:15130760|PMID:16081671 CYP2C9 Human naproxen increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of Naproxen CTD PMID:11901091|PMID:12464242|PMID:17681167 CYP2C9 Human naproxen decreases methylation EXP 6480464 CYP2C9 protein polymorphism results in decreased methylation of Naproxen; CYP2C9 protein results in decreased methylation more ... CTD PMID:15130760 CYP2C9 Human naproxen affects metabolic processing EXP 6480464 CYP2C9 gene polymorphism affects the metabolism of Naproxen; CYP2C9 protein affects the metabolism of Naproxen CTD PMID:11901091|PMID:16081671 CYP2C9 Human naringin multiple interactions EXP 6480464 naringin inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Flurbiprofen] CTD PMID:21053930 CYP2C9 Human nateglinide affects metabolic processing EXP 6480464 CYP2C9 protein affects the metabolism of nateglinide CTD PMID:18159128 CYP2C9 Human nefazodone multiple interactions EXP 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated more ... CTD PMID:33819548 CYP2C9 Human nicardipine decreases activity EXP 6480464 Nicardipine results in decreased activity of CYP2C9 protein CTD PMID:10805063|PMID:15863898 CYP2C9 Human niclosamide increases activity EXP 6480464 Niclosamide results in increased activity of CYP2C9 protein CTD PMID:11124226 CYP2C9 Human niclosamide multiple interactions EXP 6480464 Niclosamide promotes the reaction [CYP2C9 protein results in increased metabolism of Coumarins] CTD PMID:14557374 CYP2C9 Human nifedipine decreases activity ISO Cyp2c65 (Mus musculus) 6480464 Nifedipine results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human nimesulide increases glutathionylation EXP 6480464 CYP2C9 protein results in increased glutathionylation of nimesulide CTD PMID:26524229 CYP2C9 Human Notopterol multiple interactions EXP 6480464 [CYP2C9 protein results in increased metabolism of notopterol] promotes the reaction [Glutathione binds to notopterol] CTD PMID:32198085 CYP2C9 Human Notopterol increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of notopterol CTD PMID:32198085 CYP2C9 Human O-methyleugenol decreases expression EXP 6480464 methyleugenol results in decreased expression of CYP2C9 mRNA CTD PMID:32234424 CYP2C9 Human obeticholic acid decreases expression EXP 6480464 obeticholic acid results in decreased expression of CYP2C9 mRNA CTD PMID:27939613 CYP2C9 Human ochratoxin A increases expression EXP 6480464 ochratoxin A results in increased expression of CYP2C9 mRNA CTD PMID:21834667 CYP2C9 Human ochratoxin A increases response to substance EXP 6480464 CYP2C9 protein results in increased susceptibility to ochratoxin A CTD PMID:21781659|PMID:8542584 CYP2C9 Human okadaic acid decreases expression EXP 6480464 Okadaic Acid results in decreased expression of CYP2C9 mRNA CTD PMID:38832940 CYP2C9 Human okadaic acid affects expression EXP 6480464 Okadaic Acid affects the expression of CYP2C9 protein CTD PMID:38832940 CYP2C9 Human okanin decreases activity EXP 6480464 okanin results in decreased activity of CYP2C9 protein CTD PMID:29753067 CYP2C9 Human oleic acid multiple interactions ISO Cyp2c65 (Mus musculus) 6480464 PPARA protein promotes the reaction [Oleic Acid results in increased expression of CYP2C65 mRNA] CTD PMID:18489776 CYP2C9 Human omeprazole multiple interactions EXP 6480464 Omeprazole inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Diclofenac] CTD PMID:15258107 CYP2C9 Human omeprazole decreases activity ISO Cyp2c65 (Mus musculus) 6480464 Omeprazole results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human oxalic acid multiple interactions EXP 6480464 [Butyric Acid co-treated with Sulfaphenazole] inhibits the reaction [Oxalic Acid results in increased expression of more ... CTD PMID:37414240 CYP2C9 Human oxalic acid increases expression EXP 6480464 Oxalic Acid results in increased expression of CYP2C9 mRNA CTD PMID:37414240 CYP2C9 Human p-menthan-3-ol increases expression EXP 6480464 Menthol results in increased expression of CYP2C9 mRNA CTD PMID:24594507 CYP2C9 Human p-tert-Amylphenol increases response to substance EXP 6480464 CYP2C9 gene SNP results in increased susceptibility to 4-tert-octylphenol CTD PMID:23555028 CYP2C9 Human paclitaxel increases activity EXP 6480464 Paclitaxel results in increased activity of CYP2C9 protein CTD PMID:19202563 CYP2C9 Human paclitaxel decreases activity EXP 6480464 Paclitaxel results in decreased activity of CYP2C9 protein CTD PMID:19909766 CYP2C9 Human pantoprazole multiple interactions EXP 6480464 pantoprazole inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Diclofenac] CTD PMID:15258107 CYP2C9 Human paracetamol increases expression EXP 6480464 Acetaminophen results in increased expression of CYP2C9 mRNA CTD PMID:22230336 CYP2C9 Human paracetamol multiple interactions EXP 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated more ... CTD PMID:33819548 CYP2C9 Human paracetamol decreases expression EXP 6480464 Acetaminophen results in decreased expression of CYP2C9 mRNA CTD PMID:29067470 CYP2C9 Human parathion affects metabolic processing EXP 6480464 CYP2C9 protein affects the metabolism of Parathion CTD PMID:17079358 CYP2C9 Human parathion increases expression EXP 6480464 Parathion results in increased expression of CYP2C9 mRNA CTD PMID:26196221 CYP2C9 Human pedalitin decreases activity EXP 6480464 pedalitin results in decreased activity of CYP2C9 protein CTD PMID:29753067 CYP2C9 Human penconazole affects binding EXP 6480464 penconazole binds to CYP2C9 protein alternative form CTD PMID:29621561 CYP2C9 Human pentamidine decreases activity EXP 6480464 Pentamidine results in decreased activity of CYP2C9 protein CTD PMID:11124226 CYP2C9 Human perazine affects metabolic processing EXP 6480464 CYP2C9 gene polymorphism affects the metabolism of Perazine CTD PMID:11026737 CYP2C9 Human perazine decreases methylation EXP 6480464 CYP2C9 protein results in decreased methylation of Perazine CTD PMID:11026737 CYP2C9 Human perfluorohexanesulfonic acid increases expression ISO Cyp2c65 (Mus musculus) 6480464 perfluorohexanesulfonic acid results in increased expression of CYP2C65 mRNA CTD PMID:28558994 CYP2C9 Human perfluorononanoic acid increases expression ISO Cyp2c65 (Mus musculus) 6480464 perfluoro-n-nonanoic acid results in increased expression of CYP2C65 mRNA CTD PMID:28558994 CYP2C9 Human perfluorooctane-1-sulfonic acid multiple interactions EXP 6480464 perfluorooctane sulfonic acid inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Diclofenac] CTD PMID:21964418 CYP2C9 Human perfluorooctane-1-sulfonic acid multiple interactions ISO Cyp2c65 (Mus musculus) 6480464 [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of CYP2C65 mRNA; [perfluorooctane sulfonic more ... CTD PMID:20936131|PMID:36331819 CYP2C9 Human perfluorooctane-1-sulfonic acid increases expression ISO Cyp2c65 (Mus musculus) 6480464 perfluorooctane sulfonic acid results in increased expression of CYP2C65 mRNA CTD PMID:20936131 CYP2C9 Human perfluorooctanoic acid affects expression ISO Cyp2c65 (Mus musculus) 6480464 perfluorooctanoic acid affects the expression of CYP2C65 mRNA CTD PMID:18281256 CYP2C9 Human perfluorooctanoic acid multiple interactions ISO Cyp2c65 (Mus musculus) 6480464 PPARA protein inhibits the reaction [perfluorooctanoic acid results in increased expression of CYP2C65 mRNA] CTD PMID:20936131 CYP2C9 Human perfluorooctanoic acid increases expression ISO Cyp2c65 (Mus musculus) 6480464 perfluorooctanoic acid results in increased expression of CYP2C65 mRNA CTD PMID:20936131|PMID:28558994 CYP2C9 Human phencyclidine affects metabolic processing EXP 6480464 CYP2C9 protein affects the metabolism of Phencyclidine CTD PMID:16782764 CYP2C9 Human phenobarbital affects metabolic processing EXP 6480464 CYP2C9 gene polymorphism affects the metabolism of Phenobarbital CTD PMID:17304159 CYP2C9 Human phenobarbital increases expression ISO Cyp2c65 (Mus musculus) 6480464 Phenobarbital results in increased expression of CYP2C65 mRNA CTD PMID:23091169 CYP2C9 Human phenobarbital increases expression EXP 6480464 Phenobarbital results in increased expression of CYP2C9 mRNA; Phenobarbital results in increased expression of CYP2C9 more ... CTD PMID:15629111|PMID:15802389|PMID:16608920|PMID:19118567|PMID:21768169|PMID:22310298|PMID:35881160 CYP2C9 Human phenobarbital increases activity EXP 6480464 Phenobarbital results in increased activity of CYP2C9 mRNA; Phenobarbital results in increased activity of CYP2C9 more ... CTD PMID:19202563|PMID:19328226 CYP2C9 Human phenobarbital decreases activity EXP 6480464 Phenobarbital results in decreased activity of CYP2C9 protein CTD PMID:19909766 CYP2C9 Human phenobarbital multiple interactions EXP 6480464 [Progesterone co-treated with Estradiol] inhibits the reaction [Phenobarbital results in increased expression of CYP2C9 mRNA]; more ... CTD PMID:15802389|PMID:16608920|PMID:19202563|PMID:21768169 CYP2C9 Human phenprocoumon affects response to substance EXP 6480464 CYP2C9 gene polymorphism affects the susceptibility to Phenprocoumon CTD PMID:18698879 CYP2C9 Human phenprocoumon increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of Phenprocoumon CTD PMID:19082874 CYP2C9 Human phenthoate decreases activity EXP 6480464 phenthoate results in decreased activity of CYP2C9 protein CTD PMID:22634058 CYP2C9 Human phenthoate multiple interactions EXP 6480464 phenthoate inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide] CTD PMID:22634058 CYP2C9 Human phenytoin multiple interactions EXP 6480464 [Clozapine results in decreased activity of CYP2C9 protein] which results in increased susceptibility to Phenytoin; more ... CTD PMID:14600250|PMID:17961958|PMID:23397584|PMID:33961833 CYP2C9 Human phenytoin increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of Phenytoin CTD PMID:10208645|PMID:10510154|PMID:10850388|PMID:11234294|PMID:11668218|PMID:11740344|PMID:16220110|PMID:19082874|PMID:19715737|PMID:27163851 CYP2C9 Human phenytoin increases activity EXP 6480464 Phenytoin results in increased activity of CYP2C9 protein CTD PMID:19202563 CYP2C9 Human phenytoin increases hydroxylation EXP 6480464 CYP2C9 protein results in increased hydroxylation of Phenytoin CTD PMID:16873909|PMID:2025243|PMID:33961833|PMID:9110362|PMID:9860067 CYP2C9 Human phenytoin decreases metabolic processing EXP 6480464 CYP2C9 5' UTR polymorphism results in decreased metabolism of Phenytoin; CYP2C9 gene polymorphism results in more ... CTD PMID:10208645|PMID:11434505|PMID:11503012|PMID:11740344|PMID:14659971|PMID:16220110 CYP2C9 Human phenytoin decreases hydroxylation EXP 6480464 CYP2C9 gene polymorphism results in decreased hydroxylation of Phenytoin CTD PMID:16873909|PMID:9860067 CYP2C9 Human phenytoin increases expression EXP 6480464 Phenytoin results in increased expression of CYP2C9 mRNA CTD PMID:14600250 CYP2C9 Human phenytoin increases response to substance EXP 6480464 CYP2C9 gene polymorphism results in increased susceptibility to Phenytoin CTD PMID:11740344 CYP2C9 Human phenytoin affects metabolic processing EXP 6480464 CYP2C9 protein affects the metabolism of Phenytoin; CYP2C9 protein alternative form affects the metabolism of more ... CTD PMID:15855726|PMID:20405111|PMID:27163851 CYP2C9 Human phthalic acid multiple interactions EXP 6480464 [CYP2C9 protein polymorphism results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis more ... CTD PMID:23545481 CYP2C9 Human picoxystrobin decreases activity EXP 6480464 picoxystrobin results in decreased activity of CYP2C9 protein CTD PMID:23611293 CYP2C9 Human pirinixic acid increases expression ISO Cyp2c65 (Mus musculus) 6480464 pirinixic acid results in increased expression of CYP2C65 mRNA CTD PMID:17426115|PMID:18467677 CYP2C9 Human pirinixic acid multiple interactions ISO Cyp2c65 (Mus musculus) 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in more ... CTD PMID:18467677|PMID:18489776 CYP2C9 Human piroxicam multiple interactions EXP 6480464 Piroxicam inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac] CTD PMID:16081671 CYP2C9 Human piroxicam affects metabolic processing EXP 6480464 CYP2C9 gene polymorphism affects the metabolism of Piroxicam CTD PMID:11901091 CYP2C9 Human piroxicam increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of Piroxicam CTD PMID:11901091|PMID:12464242|PMID:17681167 CYP2C9 Human poly(styrene) decreases activity EXP 6480464 styrofoam analog results in decreased activity of CYP2C9 protein CTD PMID:19909766 CYP2C9 Human poly(styrene) multiple interactions EXP 6480464 styrofoam analog promotes the reaction [Cimetidine results in decreased activity of CYP2C9 protein] CTD PMID:19909766 CYP2C9 Human potassium dichromate decreases expression ISO Cyp2c65 (Mus musculus) 6480464 Potassium Dichromate results in decreased expression of CYP2C65 mRNA CTD PMID:23608068 CYP2C9 Human potassium hexacyanoferrate(3-) multiple interactions EXP 6480464 potassium ferricyanide affects the reaction [methysticin results in decreased activity of CYP2C9 protein] CTD PMID:35583123 CYP2C9 Human profenofos multiple interactions EXP 6480464 profenofos inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide] CTD PMID:22634058 CYP2C9 Human profenofos decreases activity EXP 6480464 profenofos results in decreased activity of CYP2C9 protein CTD PMID:22634058 CYP2C9 Human progesterone multiple interactions EXP 6480464 [Progesterone co-treated with Estradiol] inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein co-treated more ... CTD PMID:21768169 CYP2C9 Human propanal decreases expression EXP 6480464 propionaldehyde results in decreased expression of CYP2C9 mRNA CTD PMID:26079696 CYP2C9 Human propiconazole increases expression ISO Cyp2c65 (Mus musculus) 6480464 propiconazole results in increased expression of CYP2C65 mRNA CTD PMID:19010342|PMID:21278054|PMID:22334560|PMID:23970803 CYP2C9 Human propranolol increases oxidation EXP 6480464 CYP2C9 protein results in increased oxidation of Propranolol CTD PMID:19853591 CYP2C9 Human pyrimethamine decreases activity EXP 6480464 Pyrimethamine results in decreased activity of CYP2C9 protein CTD PMID:11124226 CYP2C9 Human quercetin multiple interactions EXP 6480464 Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with more ... CTD PMID:21053930|PMID:24120545 CYP2C9 Human quercetin decreases activity EXP 6480464 Quercetin results in decreased activity of CYP2C9 protein CTD PMID:18420780|PMID:29753067 CYP2C9 Human quercetin increases expression EXP 6480464 Quercetin results in increased expression of CYP2C9 mRNA CTD PMID:21632981 CYP2C9 Human quinidine decreases activity ISO Cyp2c65 (Mus musculus) 6480464 Quinidine results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human quinine decreases activity EXP 6480464 Quinine results in decreased activity of CYP2C9 protein CTD PMID:11124226 CYP2C9 Human quinine multiple interactions EXP 6480464 Quinine inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac] CTD PMID:16081671 CYP2C9 Human resveratrol multiple interactions EXP 6480464 [Plant Extracts co-treated with Resveratrol] results in decreased expression of CYP2C9 mRNA; Resveratrol inhibits the more ... CTD PMID:20716633|PMID:23557933 CYP2C9 Human resveratrol decreases activity EXP 6480464 Resveratrol results in decreased activity of CYP2C9 protein CTD PMID:18420780|PMID:30394306 CYP2C9 Human Rhein decreases activity EXP 6480464 rhein results in decreased activity of CYP2C9 protein CTD PMID:27633141|PMID:33438235 CYP2C9 Human rifampicin multiple interactions EXP 6480464 Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP2C9 mRNA]; NCOA6 promotes the more ... CTD PMID:14600250|PMID:14709624|PMID:15802389|PMID:16608920|PMID:19202563|PMID:21292004 CYP2C9 Human rifampicin affects response to substance EXP 6480464 CYP2C9 alternative form affects the susceptibility to Rifampin CTD PMID:36789833 CYP2C9 Human rifampicin increases activity EXP 6480464 Rifampin results in increased activity of CYP2C9 protein CTD PMID:14722322|PMID:19497360|PMID:22126990|PMID:22843569|PMID:27590069 CYP2C9 Human rifampicin increases expression EXP 6480464 Rifampin results in increased expression of CYP2C9 mRNA; Rifampin results in increased expression of CYP2C9 more ... CTD PMID:14600250|PMID:14722322|PMID:15629111|PMID:15802389|PMID:15919766|PMID:16267138|PMID:16608920|PMID:17590308|PMID:17954527|PMID:19041297|PMID:19118567|PMID:19202563|PMID:19497360|PMID:19686824|PMID:24259679|PMID:24552687|PMID:24830941|PMID:25929522|PMID:26196221|PMID:27794450|PMID:27917125|PMID:28887089|PMID:34689256 CYP2C9 Human ritonavir increases activity EXP 6480464 Ritonavir results in increased activity of CYP2C9 protein CTD PMID:19202563 CYP2C9 Human ritonavir increases expression EXP 6480464 Ritonavir results in increased expression of CYP2C9 mRNA CTD PMID:11918509 CYP2C9 Human rubiadin decreases activity EXP 6480464 rubiadin results in decreased activity of CYP2C9 protein CTD PMID:33438235 CYP2C9 Human sertraline multiple interactions EXP 6480464 CYP2C9 protein results in decreased methylation of and results in increased metabolism of Sertraline; Sertraline more ... CTD PMID:15547048|PMID:16081671 CYP2C9 Human Shikonin decreases activity EXP 6480464 shikonin results in decreased activity of CYP2C9 protein CTD PMID:28941798 CYP2C9 Human silibinin decreases activity EXP 6480464 Silybin results in decreased activity of CYP2C9 protein CTD PMID:15155549 CYP2C9 Human silicon dioxide decreases expression EXP 6480464 Silicon Dioxide analog results in decreased expression of CYP2C9 mRNA CTD PMID:25895662 CYP2C9 Human simvastatin multiple interactions EXP 6480464 Simvastatin affects the reaction [CYP2C9 polymorphism affects the susceptibility to Warfarin] CTD PMID:22594507 CYP2C9 Human sirolimus increases expression EXP 6480464 Sirolimus results in increased expression of CYP2C9 mRNA CTD PMID:25929522 CYP2C9 Human sirolimus decreases expression EXP 6480464 Sirolimus results in decreased expression of CYP2C9 protein CTD PMID:25929522 CYP2C9 Human sodium arsenite decreases expression EXP 6480464 sodium arsenite results in decreased expression of CYP2C9 mRNA CTD PMID:29301061 CYP2C9 Human sophoranone decreases activity EXP 6480464 sophoranone results in decreased activity of CYP2C9 protein CTD PMID:29753067 CYP2C9 Human sorafenib decreases activity EXP 6480464 Sorafenib metabolite results in decreased activity of CYP2C9 protein; Sorafenib results in decreased activity of more ... CTD PMID:33556367 CYP2C9 Human sporidesmin A increases expression EXP 6480464 sporidesmin results in increased expression of CYP2C9 mRNA CTD PMID:28193462 CYP2C9 Human steviol multiple interactions EXP 6480464 steviol binds to and results in decreased activity of CYP2C9 protein CTD PMID:28887089 CYP2C9 Human stevioside decreases expression EXP 6480464 stevioside results in decreased expression of CYP2C9 mRNA CTD PMID:28887089 CYP2C9 Human Sudan I increases oxidation EXP 6480464 CYP2C9 protein results in increased oxidation of 1-phenylazo-2-naphthol CTD PMID:17159775 CYP2C9 Human sulfadiazine increases hydroxylation EXP 6480464 CYP2C9 protein results in increased hydroxylation of Sulfadiazine CTD PMID:15843491 CYP2C9 Human sulfaphenazole multiple interactions EXP 6480464 [Butyric Acid co-treated with Sulfaphenazole] inhibits the reaction [Oxalic Acid results in increased expression of more ... CTD PMID:10991840|PMID:11377097|PMID:12569440|PMID:12675279|PMID:16081671|PMID:19697924|PMID:19812348|PMID:21915887|PMID:22447115|PMID:23850985|PMID:24246759|PMID:26599973|PMID:28119166|PMID:31515991|PMID:35583123|PMID:37414240 CYP2C9 Human sulfaphenazole decreases expression EXP 6480464 Sulfaphenazole results in decreased expression of CYP2C9 mRNA CTD PMID:24519941 CYP2C9 Human sulfaphenazole increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of Sulfaphenazole CTD PMID:17702393|PMID:19309152 CYP2C9 Human sulfaphenazole decreases activity EXP 6480464 Sulfaphenazole results in decreased activity of CYP2C9 protein CTD PMID:12464242|PMID:12467917|PMID:12814958|PMID:15155557|PMID:15306208|PMID:15333513|PMID:15843491|PMID:15855725|PMID:15860655|PMID:17994679|PMID:19328226|PMID:21336516|PMID:21915887|PMID:22447115|PMID:23850985|PMID:26599973|PMID:28119166|PMID:33253783|PMID:33438235 CYP2C9 Human sulfinpyrazone multiple interactions EXP 6480464 Sulfinpyrazone inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac] CTD PMID:16081671 CYP2C9 Human Sunset Yellow FCF multiple interactions EXP 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated more ... CTD PMID:33819548 CYP2C9 Human tamoxifen multiple interactions EXP 6480464 [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated more ... CTD PMID:23397584 CYP2C9 Human tamoxifen decreases activity ISO Cyp2c65 (Mus musculus) 6480464 Tamoxifen results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human tamoxifen increases activity EXP 6480464 Tamoxifen metabolite results in increased activity of CYP2C9 protein CTD PMID:29285606 CYP2C9 Human tartrazine multiple interactions EXP 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated more ... CTD PMID:33819548|PMID:34589561 CYP2C9 Human tebuconazole affects binding EXP 6480464 tebuconazole binds to CYP2C9 protein; tebuconazole binds to CYP2C9 protein alternative form CTD PMID:29621561 CYP2C9 Human tenofovir disoproxil fumarate decreases activity EXP 6480464 Tenofovir results in decreased activity of CYP2C9 protein CTD PMID:17162464 CYP2C9 Human teriflunomide increases expression EXP 6480464 teriflunomide results in increased expression of CYP2C9 mRNA CTD PMID:30364229 CYP2C9 Human testosterone decreases activity ISO Cyp2c65 (Mus musculus) 6480464 Testosterone results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human thiabendazole decreases activity EXP 6480464 Thiabendazole results in decreased activity of CYP2C9 protein CTD PMID:11124226 CYP2C9 Human thiacloprid multiple interactions EXP 6480464 [clothianidin co-treated with thiacloprid] results in increased expression of CYP2C9 protein CTD PMID:32201337 CYP2C9 Human thiacloprid increases expression EXP 6480464 thiacloprid results in increased expression of CYP2C9 protein CTD PMID:32201337 CYP2C9 Human Thiocoraline affects metabolic processing EXP 6480464 CYP2C9 protein affects the metabolism of thiocoraline CTD PMID:15122071 CYP2C9 Human thioridazine decreases activity EXP 6480464 Thioridazine results in decreased activity of CYP2C9 protein CTD PMID:15135088 CYP2C9 Human thioridazine multiple interactions EXP 6480464 [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated more ... CTD PMID:23397584 CYP2C9 Human ticlopidine multiple interactions EXP 6480464 CYP2C9 protein results in increased oxidation of and results in increased cleavage of Ticlopidine metabolite; more ... CTD PMID:19170597|PMID:21915887 CYP2C9 Human ticlopidine decreases activity EXP 6480464 Ticlopidine results in decreased activity of CYP2C9 protein CTD PMID:21915887 CYP2C9 Human tienilic acid affects metabolic processing EXP 6480464 CYP2C9 protein affects the metabolism of Ticrynafen CTD PMID:21321060 CYP2C9 Human tienilic acid increases response to substance EXP 6480464 CYP2C9 protein results in increased susceptibility to Ticrynafen CTD PMID:28762043 CYP2C9 Human tienilic acid increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of Ticrynafen CTD PMID:12464242 CYP2C9 Human tienilic acid decreases activity EXP 6480464 Ticrynafen results in decreased activity of CYP2C9 protein CTD PMID:15860655|PMID:16049126|PMID:31854189|PMID:33438235 CYP2C9 Human tienilic acid multiple interactions EXP 6480464 [[Ticrynafen results in decreased activity of CYP2C9 protein] which affects the metabolism of Diclofenac] which more ... CTD PMID:16049126|PMID:31854189 CYP2C9 Human titanium dioxide multiple interactions ISO Cyp2c65 (Mus musculus) 6480464 [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C65 more ... CTD PMID:29950665 CYP2C9 Human tolbutamide multiple interactions EXP 6480464 [CYP2C9 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of more ... CTD PMID:10611138|PMID:11377097|PMID:15370959|PMID:15856409|PMID:16081671|PMID:21915887|PMID:22634058|PMID:23850985|PMID:25994031|PMID:32198085 CYP2C9 Human tolbutamide increases metabolic processing ISO Cyp2c65 (Mus musculus) 6480464 CYP2C65 protein results in increased metabolism of Tolbutamide CTD PMID:30503582 CYP2C9 Human tolbutamide multiple interactions ISO Cyp2c65 (Mus musculus) 6480464 [CYP2C65 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of more ... CTD PMID:30503582 CYP2C9 Human tolbutamide increases hydroxylation EXP 6480464 CYP2C9 protein results in increased hydroxylation of Tolbutamide CTD PMID:10611138|PMID:12433797|PMID:15843491|PMID:2025243|PMID:22634058|PMID:25994031|PMID:26255664|PMID:26763401|PMID:9110362|PMID:9522436 CYP2C9 Human tolbutamide increases chemical synthesis EXP 6480464 CYP2C9 protein results in increased chemical synthesis of Tolbutamide metabolite CTD PMID:23850985 CYP2C9 Human tolbutamide increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of Tolbutamide CTD PMID:10208645|PMID:12464242|PMID:12467917|PMID:15155557|PMID:15370959|PMID:16124035|PMID:17267297|PMID:17565714|PMID:17702393|PMID:19082874|PMID:19715737|PMID:21915887|PMID:23850985|PMID:32198085 CYP2C9 Human tolbutamide affects metabolic processing EXP 6480464 CYP2C9 gene polymorphism affects the metabolism of Tolbutamide; CYP2C9 gene SNP affects the metabolism of more ... CTD PMID:11875364|PMID:12426520|PMID:15045499|PMID:15327588|PMID:15626586 CYP2C9 Human tolbutamide affects hydroxylation EXP 6480464 CYP2C9 protein affects the hydroxylation of Tolbutamide CTD PMID:9170147 CYP2C9 Human tolbutamide decreases hydroxylation EXP 6480464 CYP2C9 gene SNP results in decreased hydroxylation of Tolbutamide CTD PMID:9170147 CYP2C9 Human tolbutamide decreases metabolic processing EXP 6480464 CYP2C9 gene polymorphism results in decreased metabolism of Tolbutamide CTD PMID:10208645|PMID:9110362 CYP2C9 Human tolbutamide increases hydrolysis EXP 6480464 CYP2C9 protein results in increased hydrolysis of Tolbutamide CTD PMID:11377097 CYP2C9 Human torasemide increases hydroxylation EXP 6480464 CYP2C9 protein results in increased hydroxylation of Torsemide CTD PMID:9110362 CYP2C9 Human torasemide increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of Torsemide CTD PMID:19082874 CYP2C9 Human trans-cinnamic acid decreases activity EXP 6480464 cinnamic acid analog results in decreased activity of CYP2C9 protein CTD PMID:15072549 CYP2C9 Human tranylcypromine multiple interactions EXP 6480464 Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with more ... CTD PMID:24120545 CYP2C9 Human triadimefon increases expression ISO Cyp2c65 (Mus musculus) 6480464 triadimefon results in increased expression of CYP2C65 mRNA CTD PMID:23970803 CYP2C9 Human triclosan increases expression EXP 6480464 Triclosan results in increased expression of CYP2C9 mRNA CTD PMID:29849464 CYP2C9 Human triflumuron increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of triflumuron CTD PMID:31082524 CYP2C9 Human triptonide increases expression ISO Cyp2c65 (Mus musculus) 6480464 triptonide results in increased expression of CYP2C65 mRNA CTD PMID:33045310 CYP2C9 Human troglitazone decreases activity EXP 6480464 troglitazone results in decreased activity of CYP2C9 protein CTD PMID:12642470 CYP2C9 Human troglitazone multiple interactions EXP 6480464 [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated more ... CTD PMID:23397584 CYP2C9 Human tryptamines multiple interactions EXP 6480464 [Tryptamines analog results in decreased activity of CYP2C9 protein] which results in decreased metabolism of more ... CTD PMID:26599973 CYP2C9 Human tryptamines decreases activity EXP 6480464 Tryptamines analog results in decreased activity of CYP2C9 protein CTD PMID:26599973 CYP2C9 Human valproic acid decreases expression EXP 6480464 Valproic Acid results in decreased expression of CYP2C9 mRNA CTD PMID:29154799|PMID:29501571 CYP2C9 Human valproic acid increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of Valproic Acid CTD PMID:16945988|PMID:20602621 CYP2C9 Human valproic acid increases expression EXP 6480464 Valproic Acid results in increased expression of CYP2C9 mRNA CTD PMID:25084468 CYP2C9 Human valproic acid increases response to substance EXP 6480464 CYP2C9 polymorphism results in increased susceptibility to Valproic Acid CTD PMID:20398172 CYP2C9 Human valsartan affects metabolic processing EXP 6480464 CYP2C9 polymorphism affects the metabolism of Valsartan CTD PMID:34998819 CYP2C9 Human verapamil decreases activity ISO Cyp2c65 (Mus musculus) 6480464 Verapamil results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human vincristine increases response to substance EXP 6480464 CYP2C9 gene SNP results in increased susceptibility to Vincristine CTD PMID:21245421 CYP2C9 Human vitamin K multiple interactions EXP 6480464 CYP2C9 gene polymorphism affects the reaction [Vitamin K affects the susceptibility to Warfarin] CTD PMID:27462768 CYP2C9 Human voriconazole decreases activity EXP 6480464 Voriconazole results in decreased activity of CYP2C9 protein CTD PMID:15328084|PMID:15914520 CYP2C9 Human voriconazole affects metabolic processing EXP 6480464 CYP2C9 protein affects the metabolism of Voriconazole CTD PMID:15914520 CYP2C9 Human warfarin increases response to substance EXP 6480464 CYP2C9 gene mutant form results in increased susceptibility to Warfarin; CYP2C9 gene polymorphism results in more ... CTD PMID:11794436|PMID:17049586|PMID:17111199|PMID:17387222|PMID:17496169|PMID:18542936|PMID:19899329|PMID:20420818|PMID:25994031|PMID:26255664 CYP2C9 Human warfarin decreases metabolic processing EXP 6480464 CYP2C9 gene polymorphism results in decreased metabolism of Warfarin CTD PMID:20073138 CYP2C9 Human warfarin decreases hydroxylation EXP 6480464 CYP2C9 gene polymorphism results in decreased hydroxylation of Warfarin CTD PMID:11455026 CYP2C9 Human warfarin decreases response to substance EXP 6480464 CYP2C9 gene polymorphism results in decreased susceptibility to Warfarin CTD PMID:18030307|PMID:18034619 CYP2C9 Human warfarin increases hydrolysis EXP 6480464 CYP2C9 protein results in increased hydrolysis of Warfarin CTD PMID:9698079 CYP2C9 Human warfarin affects hydroxylation EXP 6480464 CYP2C9 protein affects the hydroxylation of Warfarin CTD PMID:10613612 CYP2C9 Human warfarin affects hydrolysis EXP 6480464 CYP2C9 gene polymorphism affects the hydrolysis of Warfarin CTD PMID:9698079 CYP2C9 Human warfarin affects metabolic processing EXP 6480464 CYP2C9 enhancer polymorphism affects the metabolism of Warfarin; CYP2C9 gene affects the metabolism of Warfarin; more ... CTD PMID:11307788|PMID:12621390|PMID:14586384|PMID:14676821|PMID:17332144|PMID:20073138|PMID:27539372 CYP2C9 Human warfarin decreases activity EXP 6480464 Warfarin results in decreased activity of CYP2C9 protein CTD PMID:18420780 CYP2C9 Human warfarin increases metabolic processing EXP 6480464 CYP2C9 protein results in increased metabolism of Warfarin CTD PMID:12464242|PMID:16878445|PMID:18756910|PMID:19082874|PMID:19300499|PMID:19408964|PMID:19715737 CYP2C9 Human warfarin affects abundance EXP 6480464 CYP2C9 gene polymorphism affects the abundance of Warfarin CTD PMID:25986145 CYP2C9 Human warfarin increases hydroxylation EXP 6480464 CYP2C9 protein results in increased hydroxylation of Warfarin CTD PMID:11455026|PMID:12433797|PMID:12637241|PMID:14661864|PMID:20429590|PMID:23302640|PMID:25986145|PMID:26255664|PMID:9241660|PMID:9522436 CYP2C9 Human warfarin affects response to substance EXP 6480464 CYP2C9 affects the susceptibility to Warfarin; CYP2C9 alternative form affects the susceptibility to Warfarin; CYP2C9 more ... CTD PMID:11127854|PMID:11307788|PMID:14656880|PMID:14676821|PMID:14691573|PMID:15001971|PMID:15050794|PMID:15100169|PMID:15284536|PMID:15371982|PMID:15900281|PMID:15900282|PMID:15940194|PMID:15952022|PMID:16432637|PMID:16611750|PMID:16676068|PMID:16708125|PMID:16847429|PMID:16878445|PMID:16890578|PMID:16960144|PMID:17048007|PMID:17049586|PMID:17111199|PMID:17387222|PMID:17456829|PMID:17496169|PMID:17510308|PMID:17672075|PMID:17764537|PMID:17895500|PMID:17955230|PMID:18034618|PMID:18370846|PMID:18429757|PMID:18535201|PMID:18542936|PMID:18570163|PMID:18574025|PMID:18698879|PMID:18756910|PMID:18776969|PMID:18836275|PMID:19207028|PMID:19300499|PMID:19567378|PMID:19745563|PMID:19752777|PMID:19998810|PMID:20072124|PMID:20339978|PMID:20354686|PMID:20375999|PMID:20386359|PMID:20442691|PMID:20615525|PMID:20637959|PMID:20653674|PMID:20677151|PMID:20833655|PMID:20842355|PMID:20854800|PMID:20884456|PMID:21110192|PMID:21228733|PMID:21261182|PMID:21270790|PMID:21320153|PMID:21321468|PMID:21326313|PMID:21428138|PMID:21451434|PMID:21562147|PMID:21590310|PMID:21635147|PMID:21639946|PMID:21681008|PMID:21713378|PMID:21786578|PMID:21911247|PMID:22040439|PMID:22161100|PMID:22198820|PMID:22248286|PMID:22266406|PMID:22274142|PMID:22528326|PMID:22533669|PMID:22594507|PMID:22855348|PMID:22907842|PMID:22990331|PMID:23061746|PMID:23159229|PMID:23167228|PMID:23183958|PMID:23208322|PMID:23276529|PMID:23279643|PMID:23376925|PMID:23602689|PMID:23688605|PMID:23710884|PMID:23800980|PMID:23990957|PMID:24474498|PMID:24601977|PMID:24750390|PMID:24956244|PMID:24966969|PMID:24978953|PMID:25042728|PMID:25075423|PMID:25298588|PMID:25312789|PMID:25499099|PMID:25521356|PMID:25652102|PMID:25699611|PMID:25747538|PMID:25866574|PMID:25904339|PMID:25946405|PMID:26223945|PMID:26418980|PMID:26502504|PMID:26568290|PMID:26644206|PMID:26940072|PMID:26996562|PMID:27055637|PMID:27313202|PMID:27488176|PMID:27581200|PMID:27622442|PMID:27632229|PMID:27743182|PMID:28079798|PMID:28083852|PMID:28262345|PMID:28401802|PMID:28550460|PMID:28686080|PMID:28689179|PMID:28867752|PMID:29182754|PMID:30647445|PMID:30883300|PMID:31064211|PMID:31173123|PMID:31395958|PMID:31854268|PMID:31869433|PMID:34382722|PMID:34729928|PMID:35818222|PMID:36476275|PMID:36789833 CYP2C9 Human warfarin multiple interactions EXP 6480464 10-hydroxywarfarin inhibits the reaction [[CYP2C9 protein results in increased hydroxylation of Warfarin] which results in more ... CTD PMID:10613612|PMID:16081671|PMID:19408964|PMID:20429590|PMID:20735727|PMID:22594507|PMID:26469104|PMID:27462768|PMID:27539372|PMID:31854189 CYP2C9 Human zafirlukast multiple interactions EXP 6480464 zafirlukast inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac]; zafirlukast inhibits the reaction more ... CTD PMID:15370959|PMID:16081671 CYP2C9 Human zafirlukast decreases activity EXP 6480464 zafirlukast results in decreased activity of CYP2C9 protein CTD PMID:15370959 CYP2C9 Human zearalenone decreases activity EXP 6480464 Zearalenone results in decreased activity of CYP2C9 protein CTD PMID:38341109 CYP2C9 Human zoledronic acid increases expression EXP 6480464 zoledronic acid results in increased expression of CYP2C9 mRNA CTD PMID:24714768